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ABSTRACT 
The proper targeting of membrane proteins is essential to the viability of all cells. 
Tail-anchored (TA) proteins, defined as having a single transmembrane helix at their C-
terminus, are post-translationally targeted to the endoplasmic reticulum (ER) membrane by 
the GET pathway (Guided Entry of TA proteins). In the yeast pathway, the handover of TA 
substrates is mediated by the heterotetrameric Get4/Get5 (Get4/5) complex, which tethers 
the co-chaperone Sgt2 to the central targeting factor, the Get3 ATPase. Although binding 
of Get4/5 to Get3 is critical for efficient TA targeting, the mechanisms by which Get4 
regulates Get3 are unknown. To understand the molecular basis of Get4 function, we used 
a combination of structural biology, biochemistry, and cell biology. Get4/5 binds across the 
Get3 dimer interface, in an orientation only compatible with a closed Get3, providing 
insight into the role of nucleotide in complex formation. Additionally, this structure reveals 
two functionally distinct binding interfaces for anchoring and ATPase regulation, and loss 
of the regulatory interface leads to strong defects in vitro and in vivo. Additional crystal 
structures of the Get3-Get4/5 complex give rise to an alternate conformation, which 
represents an initial binding interaction mediated by electrostatics that facilitates the rate of 
subsequent inhibited complex formation. This interface is supported by an in-depth kinetic 
analysis of the Get3-Get4/5 interaction confirming the two-step complex formation. These 
results allow us to generate a refined model for Get4/5 function in TA targeting. 
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C h a p t e r  1  
INTRODUCTION 
 
In eukaryotes, membrane proteins account for ~30% of the proteome and are 
involved in many essential functions, including cell signaling, protein transport, and 
membrane fusion 1,2. The vast majority of these proteins are initially targeted to the 
endoplasmic reticulum by the signal recognition particle (SRP) pathway. The SRP 
recognizes the first hydrophobic transmembrane domain (TMD) as it emerges from the 
ribosome exit tunnel, and then shuttles the ribosome-nascent chain (RNC) to the ER, where 
the SRP is recognized by its receptor. Docking of the RNC onto the Sec translocon then 
ensues, allowing the co-translational insertion of the nascent membrane protein into the ER 
where it adopts the correct architecture and, if necessary, enters the secretory pathway and 
is transported to the appropriate destination within the cell. This pathway has been 
extensively characterized 3,4 and is an example of highly evolved, complex biological 
macromolecules working in concert to perform a difficult task.  
 
Post-translational protein targeting 
Although the SRP pathway can target an extraordinarily wide range of membrane proteins, 
there is one class of proteins that cannot access the co-translational targeting machinery. 
Known as tail-anchored (TA) proteins, they contain a single TMD at their extreme 
carboxyl-terminus (C-terminus), and are found in nearly all membrane-bound organelles 
within the cell. As in the SRP pathway, TA proteins are first targeted to the ER, and then 
enter the secretory pathway where they are trafficked to their final destination. TA proteins 
account for ~1-2% of the eukaryotic proteome, and are involved in a wide range of 
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functions including vesicle fusion (SNAREs), apoptosis (Bcl-2), and protein translocation 
(Sec61ß) 5,6. 
Based on experiments using cytochrome b5, it was initially believed that TA 
proteins did not require any cellular machinery and spontaneously inserted into membranes 
7. However, in 1993, Kutay et al were the first to acknowledge that TA proteins would be 
unable to access the SRP pathway 8. They reasoned that because of their topological 
constraints, the TMD emerges from the ribosome only after protein synthesis is complete, 
and therefore must be targeted to the ER post-translationally. Shortly after their initial 
report, Kutay et al demonstrated that the SRP was not essential for TA targeting, but 
instead was ATP-dependent and required a membrane component at the ER distinct from 
the Sec translocon 9.  
 
Discovery of the GET pathway 
Following these initial experiments, the specific factors involved in TA targeting 
remained unknown for over a decade. Then, in 2007 Stefanovic et al used a cross-linking 
reagent to an in vitro translation system prepared from rabbit reticulocytes and managed to 
isolate a protein factor from a lysate that specifically bound TA proteins and facilitated 
their targeting in vitro10. Importantly, TA targeting by this factor was dependent on both 
ATP and the presence of a membrane component within the ER. This newly discovered 
factor, a 40 kDa cytosolic ATPase, was named the TMD Recognition Complex of 40 kDa 
(TRC40), or Guided Entry of Tail-Anchored proteins (Get3) 10,11. 
Originally annotated as ArsA or Arr4 due to its homology to the bacterial arsenite 
transport protein, homologues of TRC40 were identified in other organisms due to the high 
level of sequence conservation. Even before a link to TA targeting was known, multiple 
genetic studies provided evidence that TRC40 homologues were essential for normal 
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cellular functioning. Initial experiments with S. cerevisiae demonstrated knockouts were 
sensitive to increased temperatures and metal tolerance, much like the bacterial ArsA 12,13. 
Growth phenotypes were also observed in higher eukaryotes. A Caenorhabditis elegans (C. 
elegans) knockout arrested development at the L1 stage 14, while a mouse knockout was 
embryonic lethal 15. Downregulation of TRC40 in human melanoma cells increased their 
sensitivity to arsenite and cisplatinin, a cancer therapeutic, providing a link to human 
disease 16.  
Prior to the discovery of TRC40, genetic studies in the budding yeast S. cerevisiae 
established a link between Arr4 and a complex of two resident ER membrane proteins 
(MDM39 and RMD7) 17. Furthermore, these factors were implicated in Golgi to ER traffic 
(GET), and renamed Get1 (MDM39), Get2 (RMD7), and Get3 (Arr4). Subsequent studies 
demonstrated that Get3 formed a physical interaction with the protein complexes 
Get1/Get2 (Get1/2) 18,19 and Get4/Get5 20, and that all five functioned directly in TA 
targeting. This led to the acronym GET to be redefined as the Guided Entry of Tail-
Anchored proteins. Evidence from two separate genetic analyses suggested that an 
additional factor, the heat shock protein (HSP) co-chaperone Sgt2, also played a role in TA 
targeting, and most likely functioned upstream of Get4/5 21,22. 
 
Characterizing the GET pathway 
Extensive structural characterization of Get3, the central TA targeting factor, 
demonstrated that it undergoes ATP-dependent conformational changes from an open to 
closed form required for capturing the TA substrate 23-28. Once formed, the Get3-TA 
complex is then localized to the ER by the membrane proteins Get1/2, which stimulate 
release of the TA protein and subsequent insertion into the ER membrane 29-32. Crystal 
structures of Get3 in complex with the soluble domains of Get1 and Get2 revealed 
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overlapping binding sites on Get3, suggesting that Get1 and Get2 bind independently in 
vivo 29,30. This was further supported by the observation that the soluble domain of Get2 
crystallized with both the open and closed forms of Get3, whereas the soluble domain of 
Get1 crystallized with only the open form. Rome et al (2014) subsequently demonstrated 
that Get2 has the highest affinity to ADP-bound Get3, whereas Get1 prefers apo-Get3, 
suggesting that Get2 binding precedes Get1. In fluorescence microscopy experiments with 
yeast Get3 or Get1/2 knockout strains, the majority of TA proteins were either mistargeted 
(Get3), or formed aggregates in the cytosol (Get1/2), underscoring the importance of these 
factors in vivo 19. 
Upstream of Get3 is the multi-domain co-chaperone Sgt2 that specifically binds the 
TA, which is the first committed step in TA targeting 22,33,34. Sgt2 forms an extended 
protein in solution and is comprised of three domains: an amino-terminal (N-terminal) 
dimerization domain, a middle tetratricopeptide repeat (TPR) domain, and C-terminal 
glutamine-rich (Q) domain. NMR structures of the dimerization domain by itself and in 
complex with the ubiquitin-like (Ubl) domain of Get5 were recently published 35. These 
structures, along with a comprehensive binding analysis, revealed that this interaction is 
mainly electrostatic and occurs on fast timescales. Disruption of this interaction in yeast 
leads to similar growth defects seen with the Get3 knockout 36,37. Structural studies of the 
TPR domain provided a model for how Sgt2 might interact with upstream chaperones 33. 
The Q domain, which binds the TMD of the nascent TA protein, has so far evaded both 
NMR and protein crystallography due its inherent flexibility. 
Efficient delivery of a TA substrate to Get3 requires the hetero-tetrameric Get4/5 
complex that provides the link between Sgt2 and Get3 21,22,34,38. Structural studies of Get4 
and the N-terminal domain of Get5 revealed that Get4 is an alpha-helical repeat protein, 
with the N-terminus of Get5 wrapping around its C-terminus 36,39. Size-exclusion 
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chromatography (SEC) demonstrated that formation of the Get4/5 heterotetramer was 
dependent on dimerization of the Get5 C-terminus 36. In SAXS reconstructions, the full-
length Get4/5 complex forms an extended structure where Get4 flanks the Get5 Ubl 
domain and central Get5 C-terminal homodimerization domain 33,36,40. 
More recent work has expanded on the role of Get4/5 in TA targeting beyond 
acting as a simple bridge. In addition to preferentially recognizing a nucleotide bound Get3, 
Get4 inhibits Get3 ATP hydrolysis 41. TA binding is the presumptive trigger for hydrolysis 
41, thus Get4 helps to stabilize Get3 in a conformation competent for TA binding. Initial 
biochemical and genetic evidence implicated the N-terminal face of Get4 in Get3 binding 
36,42, but additional evidence was lacking until recently. This report showed that Get4 
bound to Get3 on near-diffusion limited timescales, and that one phase of the association 
was salt-dependent, suggesting that electrostatic interactions play a role in complex 
formation 43.   
Although our understanding of the pathway has increased in the last decade, there 
are many questions that remain unanswered. One important question is how Get4 regulates 
Get3 activity, i.e., what is the structural basis of Get4 function. The work presented here 
answers these questions and gives insight into the role of the Get3-Get4/5 interaction 
during TA protein targeting. Chapter 2 presents the crystal structure of an ATP-bound 
Get3-Get4/5 complex. This structure provides insight into the role of nucleotide in complex 
formation, where Get4 binds to both monomers of Get3 in an orientation only compatible 
with a closed Get3 and revealed two functionally distinct binding interfaces for anchoring 
and ATPase regulation. Chapter 3 presents two additional crystal structures of the Get3-
Get4/5 complex in an alternate conformation. These structures represent an initial binding 
interaction mediated by electrostatics that facilitates the rate of subsequent inhibited 
complex formation. This is supported by kinetic analysis of Get3-Get4/5 complex 
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formation confirming the two-step complex formation. Chapter 4 presents unpublished 
work towards solving the crystal structure of a full-length Get3-Get4/5 complex, and 
concludes the thesis with a review of the key findings and insight into possible future 
experiments that may help further our understanding of the Get3-Get4/5 interaction and the 
roles it plays in TA targeting.  
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C h a p t e r  2  
CRYSTAL STRUCTURE OF ATP-BOUND GET3-GET4-GET5 COMPLEX REVEALS 
REGULATION OF GET3 BY GET4 
 
Abstract 
Correct localization of membrane proteins is essential to all cells. Chaperone cascades 
coordinate the capture and handover of substrate proteins from the ribosome to their target 
membrane; yet the mechanistic and structural details of these processes remain unclear. Here 
we investigate the conserved GET pathway, in which the Get4/Get5 complex mediates the 
handover of tail-anchor (TA) substrates from the co-chaperone Sgt2 to the Get3 ATPase, the 
central targeting factor. We present a crystal structure of a yeast Get3-Get4/Get5 complex in an 
ATP-bound state, and show how Get4 primes Get3 into the optimal configuration for substrate 
capture. Structure-guided biochemical analyses demonstrate that Get4-mediated regulation of 
ATP hydrolysis by Get3 is essential to efficient TA protein targeting. Analogous regulation of 
other chaperones or targeting factors could provide a general mechanism for ensuring effective 
substrate capture during protein biogenesis.  
  
 
 
 
 
 
Adapted from 
Gristick, H.B., Rao, M., Chartron, J. W., Rome, M. E., Shan, S. O., and Clemons, W.M., Jr. 
Crystal structure of ATP-bound Get3-Get4-Get5 complex reveals regulation of Get3 by Get4. 
Nat Struct Mol Biol 21, 437-42 (2014).  
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Introduction 
In eukaryotes, the proper targeting of membrane proteins is a significant challenge for 
the cell to overcome 44. Integral membrane proteins contain hydrophobic transmembrane 
domains (TMD), which must be protected from the aqueous cytosolic environment prior to 
integration into the appropriate membrane. For the majority of membrane proteins targeted to 
the endoplasmic reticulum (ER), this is accomplished by the signal recognition particle (SRP), 
typically binding the initial TMD, or signal anchor, as it emerges from the ribosome and targets 
it to the ER for co-translational insertion. Exceptions are the ubiquitous tail-anchor (TA) 
proteins, defined topologically by a single transmembrane domain near the C-terminus, which 
are unable to access the SRP pathway and must be targeted to the ER post-translationally 8,9. 
Found in most cellular membranes, TA proteins are targeted to either the ER or 
mitochondria. For the latter, a dedicated pathway has not been identified 45. Those destined for 
other organelles are initially targeted to the ER, and then subsequently trafficked to the 
appropriate membrane 9. Examples include many essential proteins such as SNAREs (vesicle 
fusion), Bcl-2 (apoptosis), and Sec61γ (protein translocation machinery) 46. A need for specific 
targeting of ER destined TA proteins was first conceptualized nearly two decades ago 8 and the 
cellular factors responsible have now been identified. The central targeting factor was 
identified biochemically in a mammalian system as the cytosolic ATPase TRC40, 
demonstrated to bind the TA and deliver it specifically to the ER 10,11. Previous genetic 
experiments involving the yeast homolog, Get3, could then be linked to TA targeting, 
providing a route for studying this process 17. This was followed by a series of results that 
characterized the new pathway, termed GET (Guided Entry of TA proteins) 19,20,22. In yeast, 
this pathway consists of six proteins, Get1-5 and Sgt2, all with homologs in higher eukaryotes 
(Reviewed in Ref. 12).  
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Structural characterization of Get3, the central TA targeting factor, demonstrates that it 
undergoes ATP-dependent conformational changes from a apo ‘open’ to an ATP-bound 
‘closed’ form required for capturing the TA substrate 23-27,47. Deletion of Get3 in yeast leads to 
a buildup of mislocalized cytosolic TA proteins 19 and is embryonic lethal in mice 15. The Get3-
TA complex is recruited to the ER by the membrane proteins Get1-Get2 (Get1-2) 29-31. These 
stimulate release of the TA protein and subsequent insertion into the ER membrane, although 
the specifics of this mechanism are, as yet, unknown. Upstream of Get3 is the multi-domain 
Hsp70 or Hsp90 co-chaperone Sgt2 22,33,34 that specifically binds the TA, the first committed 
step in TA targeting, followed by hand-over to Get3 34. 
Efficient delivery of a TA substrate to Get3 requires the hetero-tetrameric Get4-Get5 
(Get4/5) complex that provides the link between Sgt2 and Get3 21,22,34. Structural studies of 
Get4 and the N-terminal domain of Get5, also called Mdy2, revealed that Get4 is an alpha-
helical repeat protein, with the N-terminus of Get5 wrapping around its C-terminus 36,39. 
Biochemical and genetic evidence implicated the N-terminal face of Get4 in Get3 binding at an 
interface that shared commonalities with the binding sites for Get1 and Get2 36,39. In SAXS 
reconstructions, the full-length Get4/5 complex forms an extended structure where Get4 flanks 
the Get5 ubiquitin-like domain (Ubl) and central Get5 C-terminal homodimerization domain 
33,36,40. Initial results suggested that binding of Get4 to Get3 required nucleotide 36; however, a 
subsequent publication has brought this into question 42. More recent work has expanded on the 
role of Get4/5 in TA targeting beyond acting as a simple bridge. In addition to preferentially 
recognizing a nucleotide bound Get3, Get4 inhibits Get3 ATP hydrolysis 41. TA binding is the 
presumptive trigger for hydrolysis 41, and thus Get4 helps to stabilize Get3 in a conformation 
competent for TA binding. Since a major outstanding question is how Get4 regulates Get3 
activity, we set out to understand the structural basis of Get4 function. 
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This report describes the 5.4 Å crystal structure of an ATP-bound Get3-Get4/5 complex 
from Saccharomyces cerevisiae (Sc), a combined ~160 kDa hetero-hexameric structure. Two 
functionally distinct binding interfaces for anchoring and ATPase regulation were found 
between Get3 and Get4, and were confirmed biochemically and genetically. Mutations at these 
interfaces demonstrated that Get4/5-mediated regulation of ATP hydrolysis by Get3 was 
critical for efficient TA targeting. Finally, crystallographic tetramers of Get3 are compatible 
with two Get3 dimers bridged by a single Get4/5 hetero-tetramer. In total, this work illustrates 
how Get4/5 regulates Get3, priming it for TA loading, which is a critical step in this important 
pathway.  
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Results 
Get4/5 binds the ATP-bound state of Get3 
It was first important to establish the requirements for forming a stable Get3-Get4/5 
complex. Unless noted, Get3 is either wild type or contains an ATPase inactivating mutation 
(D57V, referred to as Get3D) that prevents ATP hydrolysis while still allowing ATP binding. 
Get4/5 is either the wild-type hetero-tetramer (Get4/5) or a 22 residue C-terminal truncation of 
Get4 (1-290) and the 54 residue N-terminal domain of Get5 (Get4/5N), similar to that used in a 
crystal structure of the heterodimer 36. As observed previously 42, in low salt (10 mM NaCl) a 
1:1 complex of Get3D bound to Get4/5N could be generated that was stable by size-exclusion 
chromatography (SEC) (Figure 2.1A, yellow trace). Increasing the salt concentration resulted 
in a loss of complex formation such that no complex could be detected at 500 mM NaCl 
(brown trace), suggesting an electrostatic interaction. At near physiological conditions (175 
mM NaCl), a complex between Get3D-Get4/5 was disfavored (dark red trace), suggesting that 
additional factors were required to stabilize the complex in vivo. 
Based on previous evidence that suggested a role for nucleotide in complex formation 
36, a variety of assays were tested to confirm nucleotide stabilization of the Get3D-Get4/5N 
complex. SEC was performed in the presence of nucleotide at a salt concentration where the 
complex was disfavored (250 mM NaCl) (Figure 2.1A-B, orange trace). For ADP, a clear 
stabilization of the complex was seen (Figure 2.1B, green trace) while ATP resulted in the 
most stable complex (blue trace), consistent with previous experiments 36,41. Additionally, pull-
down experiments were quantified where tagged Get4/5N was used to precipitate Get3D with 
binding presented as a ratio of the two. These experiments confirmed the nucleotide-
dependence as observed with SEC demonstrating a preference for ATP (Figure 2.1C). Finally, 
affinity constants (Kd) were measured using isothermal titration calorimetry (ITC) at a 
physiological ionic strength (150 mM KOAc) (Figure 2.1D and Supplementary Figure 2.1). 
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For an apo-Get3D, a Kd could not be measured, suggesting that the affinity was less than 10 
µM. In the presence of ADP, Get4/5N binds to Get3 with micromolar affinity that increases to 
~500 nM with ATP. Collectively, all three assays show that Get4/5 preferentially interacts with 
ATP-bound Get3 at physiological ionic strength conditions.  
 
Architecture of the Get3-Get4/5 complex 
While it is clear that Get4 recognizes the ATP-bound state of Get3, the structural details 
of this interaction were missing. To understand these, a complex of ATP, Get3D and Get4/5N 
was crystallized and a structure was determined to 5.4 Å resolution (Table 2.1). In the 
structure, there is a 1:1 ratio of Get3D to Get4/5N. Get3 is in a ‘closed’ conformation, as 
anticipated based on ATP being bound 24, with the Get4 interaction lying across the dimer 
interface (Figure 2.2). An ‘anchoring’ (see below) interface (primarily to the brown Get3 in 
Figure 2.2) buries ~920 Å2 surface area, while a ‘regulatory’ interface (primarily to the purple 
Get3) contributes ~400 Å2 to this interaction (Supplementary Figure 2.2). 
At the anchoring interface, Get4 α2 makes extensive contacts roughly parallel to the 
groove formed by Get3 α10 and α11 (Figure 2.3A and Supplementary Figure 2.3, we have 
included side-chains for clarity despite the resolution). This results in an interaction between 
the invariant residues Phe246 and Tyr250 on Get3 α10 and Tyr30 on Get4 α2 (Figure 2.3A-B 
and Supplementary Figure 2.2B-C). In addition to these hydrophobic contacts, a number of 
highly conserved charged residues are located within this interface (Get3: Glu253, Gln257, 
Glu258, Glu304, Asp308, and Get4: Arg37, Arg42). In contrast to α2, Get4 α1 is located on the 
opposite face relative to Get3, and makes fewer contacts. However, the N-terminus of Get4 α1 
is tilted toward Get3, placing the conserved charged residues Lys15 and Arg19 in close 
proximity to Get3 α10. Previously, this group had demonstrated that residues on the N-terminal 
face of Get4 bound Get3 residues at a similar surface to that demonstrated for the ER receptors 
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Get1 and Get2 29,30,36. A number of these residues map to the anchoring interface (Get3: 
Tyr250, Glu253 and Get4: Arg19, Tyr30, Arg37, Arg42) (Figure 2.3A and Supplementary 
Figure 2.2A). 
At the regulatory interface, located on the opposing monomer, the C-terminal end of 
Get4 α4 packs against the loop following Get3 α3 (Figure 2.3A-B and Supplementary Figure 
2.3). This places a number of highly conserved complementary charged residues within this 
interface (Get3: Lys69, Lys72, Arg75 and Get4: Asp74, Glu81). Central to this interaction are 
the invariant residues Lys69 (Get3) and Asp74 (Get4), which are located opposite one another.  
 
Mutational analysis of the Get3–Get4 interface 
As noted above, the extensive Get3–Get4 interface involves varied contacts to both 
monomers. ITC and affinity capture assays were performed to determine which residues are 
essential for binding (Figure 2.3 and Supplementary Figure 2.1). As expected, alanine 
substitution of the invariant hydrophobic residues (Get3: Phe246, Tyr250 and Get4: Tyr30) 
dramatically reduced the binding affinity. In addition, a number of the conserved charged 
residues within the anchoring interface (Get3: Glu253, Glu304 and Get4: Arg19, Arg37, 
Arg42) produced similar effects following their substitution. A moderate binding defect was 
seen with Ala substitutions of the remaining residues on Get3 α10 (Gln257, Glu258) and the 
loop following Get3 α11 (Asp308). Substitution of the remaining residues on Get4 (Get4: 
Lys15, Lys23, Tyr29, Glu31, His33, Gln34, Arg45), which are located farther away from the 
core of the anchoring interface and of lower sequence conservation, had little to no effect on 
binding. 
At the regulatory interface, several highly conserved basic residues in Get3 (Lys69, 
Lys72, Arg75) are in close proximity to oppositely charged residues in Get4 (Asp74, Glu81). 
Nevertheless, substitution of these Get3 residues by Ala or Asp has little to no effect on Get4 
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binding (Figure 2.3C). Furthermore, substitution of Get4 Asp74 by Lys resulted in a marginal 
increase in Kd ~1 µM as determined by ITC (Figure 2.3C). Collectively, these studies revealed 
that the anchoring interface is mainly responsible for the specificity of binding between Get3 
and Get4. 
 
Regulation of Get3 nucleotide hydrolysis 
While the regulatory interface is not involved largely in binding, the highly conserved 
nature of residues at this interface suggests they play an alternative role in TA targeting. 
Recently published work demonstrated that Get4/5 binding results in inhibition of Get3 ATP 
hydrolysis 41. To test if this interface plays a role, kcat was determined for several mutants of 
Get3 in the absence and presence of Get4–5 (Supplementary Table 2.1). The results are 
presented as a ratio (-Get4/5:+Get4/5) where a larger number indicates inhibition by Get4/5, 
e.g., wild-type Get4/5 inhibits Get3 ~6-fold (Figure 2.4A). Consistent with their binding 
defects, the Get3 mutants E253K and E304K were not inhibited by Get4/5 (Figure 2.4A). 
Notably, Get3 K69D, situated at the regulatory interface, significantly lost the ability to be 
inhibited by Get4/5 (Figure 2.4A), although it bound Get4/5 with similar affinities to wild type 
(Figure 2.3C). A Get3 K72D mutant also lost the ability to be inhibited by Get4–5 relative to 
wild-type, albeit to a smaller extent (Supplementary Table 2.1). Mutation of the invariant 
Get4 Asp74, situated opposite Get3 Lys69 (Figures 2.3B and 2.4C and Supplementary 
Figures 2.2B-C and 2.3), yielded the same phenotype (Figures 2.3C and 2.4A). Importantly, 
combining both opposing mutants (Get3 K69D/Get4 D74K) restored the ability of Get4–5 to 
regulate Get3 ATPase activity, demonstrating that these two residues directly interact (Figure 
2.4A). This is again consistent with the high conservation of residues located on either side of 
this interface (Figure 2.3B and Supplementary Figure 2.2B-C). These results demonstrate 
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that Get4 plays two distinct roles for Get3, recruitment and regulation, which can be 
biochemically decoupled. 
To test whether the regulation of Get3 ATPase activity is important for TA targeting, a 
reconstituted in vitro targeting assay was used 41. Specifically, a TA-substrate, Sbh1, was 
translated in ∆get3 yeast extracts and targeted to ER microsomes by exogenously added Get3. 
The efficiency of targeting is then reported by the glycosylation of an engineered opsin tag on 
Sbh1 upon insertion into microsomes. Mutant Get3 K69D exhibits a ~40% loss of Sbh1 
insertion compared to wild-type, which agrees with its loss in Get4/5-induced regulation of 
ATPase activity (Figure 2.4A-B and Supplementary Figure 2.4A). Importantly, this effect is 
only seen in the presence of Get4/5 as both wild-type Get3 and Get3 K69D have the same 
targeting efficiency using translation extracts from a ∆get3/∆mdy2 strain (Get4 is depleted in 
this strain34) (Supplementary Figure 4B-C). This is distinct from Get1-2 binding mutants as 
the critical E253K mutant (that cannot bind Get1 or Get2) 29-31 completely abolishes insertion 
in both ∆get3 and ∆get3/∆mdy2 extracts (Supplementary Figure 4B-C), which demonstrates 
that the Get3 K69D mutant does not directly affect the membrane-associated steps. The 
formation of functional Get3-TA complexes likely follows a mechanism similar to wild-type in 
these mutants, as the data still fits a Hill coefficient of 2, previously shown to correlate with 
Get3 tetramer formation 41. In addition, the targeting by Get3 K69D cannot be rescued by 
increasing protein concentration (Figure 4B), consistent with a model in which premature ATP 
hydrolysis in this mutant reduces the fraction of productive Get3-Get4/5 complexes that can 
capture and target the TA substrate. Thus, Get4/5-induced delay of ATP hydrolysis from Get3 
is integral for ensuring efficient TA protein targeting.  
To examine whether this regulation is important for Get3 function in vivo, the ability of 
Get3 K69D and Get4 D74K to rescue known knockout phenotypes was tested using a yeast 
growth assay 19,23,36. As before, neither ∆get3 nor ∆get4 strains showed a phenotype when 
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grown on synthetic complete media at 30oC. However, growing these strains at 40oC in the 
presence of 2mM Cu2+ produced a strong phenotype that could be rescued by expression of the 
wild-type protein on a plasmid (Figure 2.4D). A Get3 K69D mutant was unable to fully rescue 
the growth phenotype supporting a role for regulation in vivo. A Get4 D74K mutant was also 
unable to fully rescue, resulting in an even stronger phenotype than the Get3 K69D mutant 
(Figure 2.4D). It is important to note that this surface of Get4 has no other known interacting 
partners, meaning that this phenotype can only be readout of the regulatory role of Get4. In 
total, these results provide strong evidence that Get4/5-mediated regulation of Get3 ATPase 
activity is critical for a functional GET pathway. 
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Discussion 
The structure of the Get3-Get4/5 complex presented here reveals the molecular basis of 
Get3 recognition by Get4. In particular, the structure provides insight into the role of nucleotide 
in complex formation, where Get4 binds to both monomers of Get3 in an orientation only 
compatible with a closed Get3. The anchoring interface was demonstrated to mediate the 
interaction between Get3-Get4, while the regulatory interface is critical for inhibition of Get3 
ATP activity. This regulation of Get3 is necessary for efficient targeting in vitro and loss of 
regulation leads to growth defects in vivo. While it is difficult to speculate at sub-atomic 
resolution, it is interesting to note that Get3 Lys69 connects through a short helix to the critical 
Switch I loop that contains the catalytic D57. This would make the interaction between Get4 
Asp74 and Get3 Lys69 allosteric, leading to inactivating conformational changes in the 
catalytic pocket.  
There is growing evidence that the soluble Get3-TA complex contains a tetramer of 
Get3, in which two copies of the dimer form a hydrophobic chamber 28,41. A tetramer of Get3 is 
observed in the Get3-Get4/5 crystal packing that is strikingly similar to the tetramer structures 
seen in the archaeal Get3 homolog 28 and in the crystal packing of the Get2-Get3 complex 30 
(Figure 2.5A-B and Supplementary Figure 2.5). If one considers the orientations of the Get4 
monomers across the tetramer, the distances are compatible with the requirement that they be 
bridged by the rest of the Get5 dimer (Figure 2.5A) 33. In contrast, while a Get3 dimer presents 
two potential Get4 binding sites, a single Get4/5 hetero-tetramer would be unable to occupy 
both, as this would require steric clashes to Get3. The tetramer seen here then likely represents 
a pre-hydrolysis Get3 complex waiting for a TA substrate to trigger hydrolysis and release of 
the complex from Get4. 
Coupling this structural data and biochemistry with the current literature allows us to 
provide a refined model for TA selection by the Get3-Get4/5 complex (Figure 2.5C). (1) In the 
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absence of nucleotide Get3 is predominantly in the open conformation with low affinity for 
Get4/5. (2) Binding of ATP would shift Get3 to a closed conformation that would be 
recognized by Get4/5, and promote inhibition of Get3 ATPase activity. (3) A second Get3 
dimer binding to the Get4/5 hetero-tetramer would follow. The complex would now be primed 
for capture of a TA substrate from the co-chaperone Sgt2 24 bound to the Ubl-domain of Get5 
40. (4) The stabilized tetramer-TA complex results in ATP hydrolysis 41 causing release from 
Get4 and subsequent delivery to the ER.  
In all organisms, cascades of protein biogenesis factors mediate the chaperoning and 
handover of nascent proteins from the ribosome to their final folding state or cellular 
destination. Active regulation of the conformation and nucleotide state of protein biogenesis 
factors, as studied here for Get3, has also been observed for the SRP-SRP receptor complex 
during co-translational protein targeting 48,49. This likely represents a general mechanism for 
ensuring efficient and productive biogenesis of nascent proteins. 
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Methods 
Protein cloning, expression, and purification 
The sequences of Get4 and Get5 were cloned as previously described 36. To generate 
the Get4/5N used in this study, this construct was further modified by truncating the C-
terminus of Get4 (residues 291-312), and by the addition of a stop codon after residue 54 
within Get5. All S. cerevisiae Get4 mutants were generated using the QuikChange mutagenesis 
method (Stratagene) and verified by DNA sequencing. All Get4/5 proteins were overexpressed 
in BL21-Gold (DE3) (Novagen) grown in 2xYT media at 37 °C and induced for 3h by the 
addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). Cells were lysed using a 
microfluidizer (Microfluidics) and purified as a complex by Ni-affinity chromatography 
(Qiagen). The affinity tag was removed by an overnight TEV protease digest at room 
temperature while dialyzing against 20 mM Tris pH 7.5, 30 mM NaCl, and 5 mM β-
mercaptoethanol (BME). A second Ni-NTA column was used to remove any remaining his-
tagged protein, and the sample was then loaded onto a 6 mL Resource Q anion exchange 
column (GE Healthcare). The peak containing the Get4/5N complex was collected and 
concentrated to 15-20 mg/mL. Initial purifications of the Get4/5N complex were verified to be 
a single monodispersed species over SEC using a Superdex 200 16/60 column (GE Healthcare) 
equilibrated with 20 mM Tris pH 7.5, 100 mM NaCl, and 5 mM BME. Full-length Get4/5 used 
in ATPase assays and translocation experiments was further purified using a Superdex 200 
16/60 column (GE Healthcare) equilibrated with 20 mM K-HEPES pH 7.5, 150 mM KOAc, 10 
mM MgOAc, 10% (v/v) Glycerol, and 5 mM BME. Fractions containing Get4/5 were pooled 
and concentrated to ~5 mg/mL. 
The S. cerevisiae Get3 coding region was cloned as previously described 23. A 6xHis-
tag followed by a tobacco etch virus (TEV) protease site was fused to the N-terminus, and a 
stop codon was placed in front of the C-terminal 6xHis-tag. All S. cerevisiae Get3 mutants 
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were generated using the QuikChange method. Get3 mutants used in SEC, ITC, or capture 
assays were introduced into the Get3D construct, whereas mutants used in ATPase assays or 
translocation assays were introduced into the wildtype Get3 construct. All Get3 proteins were 
made in BL21-Gold(DE3), grown in 2xYT media, and induced with 0.5 mM IPTG for 16h at 
22oC. Cells were lysed using a microfluidizer (Microfluidics) and purified by Ni-affinity 
chromatography (Qiagen). The affinity tag was removed by an overnight TEV protease digest 
at room temperature while dialyzing against 20 mM Tris pH 7.5, 100 mM NaCl, and 5 mM 
BME. A second Ni-NTA column was used to remove any remaining his-tagged protein, and 
then the sample was run on a Superdex 200 16/60 column (GE Healthcare) equilibrated with 
the dialysis buffer. Fractions corresponding to a dimer of Get3 were pooled and concentrated to 
15-20 mg/mL. Get3 derivatives used for ATPase assays and translocation experiments were 
further purified over a MonoQ anion exchange column to remove contaminating ATPases. 
Get3D-Get4/5N complex was formed by equilibrating 105 µmol Get4/5N with 100 
µmol Get3D at room temperature in 500 µL of 20mM Tris pH 7.5, 10mM NaCl, 5mM BME, 
1mM MgCl2, and 1mM of either AMP-PNP or ATP. Prior to complex formation, Get3 had 
been pre-equilibrated with 1mM MgCl2 and either 1mM AMP-PNP or ATP for 5 min at room 
temperature. Get3-Get4/5N complex was further separated from free Get4/5N using a 
Superdex 200 10/300 (GE Healthcare) equilibrated with 20 mM Tris pH 7.5, 10 mM NaCl, and 
5 mM BME or with 20 mM Bis-Tris Propane pH 9.0, 10 mM NaCl, and 5 mM BME. All 
complexes were concentrated to 10-12 mg/mL before use in crystallization experiments. 
 
Crystallization 
Purified Get3D-Get4/5N complex was concentrated to 10-12 mg/ml and crystal trials 
were carried out using the sitting-drop vapor diffusion method at room temperature by 
equilibrating equal volumes of the protein complex solution and reservoir solution using a TTP 
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LabTech Mosquito robot and commercially purchased kits (Hampton Research, Qiagen, 
Molecular Dimensions Limited). Get3D-Get4/5N crystals grew in the presence of 18% PEG 
3350, 0.2 M KSCN, 0.1 M Bis-Tris Propane pH 9.0, and 5% DMSO. Crystals were 
cryoprotected by transferring directly to 10µL of a reservoir solution supplemented with 20% 
glycerol, 1mM ATP, and 1 mM MgCl2 and incubated for ≥10 minutes before being flash 
frozen in liquid nitrogen.  
 
Data collection, structure solution, and refinement 
All structures were solved using datasets collected on Beamline 12-2 at the Stanford 
Synchrotron Radiation Lightsource (SSRL) at 1 Å at ~100 K. Each structure was solved from a 
single dataset that was integrated using MOSFLM 50 or XDS 51, and scaled and merged using 
SCALA 52,53. Crystals of Get3D-Get4/5N diffracted to 5.4 Å and was solved by molecular 
replacement with PHASER 54 as implemented in PHENIX 55, using a monomer of the closed 
(ADP-AlF4) form of Get3 (PDB ID 2WOJ 24) and one Get4/5N heterodimer (PDB ID 3LKU 
36) as search models. No solution was found using the open (apo) form of Get3 (3A37 27). 
Refinement was performed using REFMAC v6.3 with rigid body restraints and in CNS v1.2 56 
using DEN refinement. Manual rebuilding was performed using COOT 57. The final model 
refined to an R-factor of 27.0% (Rfree = 32.8%) with residues in the Ramachandran plot in 
92.2% preferred, 6.0% allowed, and 1.8% in the disallowed and restricted regions 57. Full 
statistics in Table 1. 
 
Size exclusion chromatography for complex stability 
250 µL of 25 µM Get3D and 250 µL of 25 µM Get4/5N were combined and dialyzed at 
room temperature in 20 mM Tris pH 7.5, 10 mM NaCl, 5 mM BME, 1 mM MgCl2, and, where 
indicated, 1 mM of either ADP or ATP. The total samples were injected onto a Superdex 200 
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10/300 (GE Healthcare) equilibrated in 20 mM Tris pH 7.5, 10-500 mM NaCl, and 5 mM 
BME. 
 
Capture assay 
500 nmol of 6xHis-tagged Get4/5N was incubated with 10 µL Ni-NTA agarose resin 
for one hour at 4oC in 500 µL binding buffer containing 20 mM K-HEPES pH 7.5, 150 mM 
KOAc, 10 mM MgOAc, 10% (v/v) Glycerol, 25 mM imidazole, and 1 mM ADP or ATP 
where indicated. Following the addition of 1 µmol of Get3D, the solution was incubated for an 
hour at 4oC. After incubation, the reaction was spun for 30 sec at 500xg. The supernatant was 
removed, and 500 µL binding buffer was added to the solution and gently mixed through 
inversion. The wash step was repeated twice, and following the final wash, the remaining 
bound proteins were eluted with 30 µL of 20mM Tris pH 7.5, 100 mM NaCl, 5mM BME, and 
300 mM imidazole. The samples were spun for 30 sec at 500 x g, and the supernatant was 
removed and added to 6 µL of 6xSDS-PAGE buffer. All samples were run on 15% SDS-PAGE 
gels and stained with Coomasie blue G-250. Gels were then analyzed by infared scanning in 
the 700 nm channel using a LI-COR Odyssey Infared Imaging System and Odyssey 
Application Software v3.0.30. 
 
Isothermal titration calorimetry 
Get3D-Get4/5N binding experiments were carried out using the MicroCal iTC200 
system (GE Healthcare). Binding affinities were measured by filling the sample cell with 50 
µM Get3D and titrating 350 µM Get4/5N. The buffer conditions were identical for all samples 
and contained 20 mM K-HEPES pH 7.5, 150 mM KOAc, 10 mM MgOAc, 10% (v/v) 
Glycerol, and 1mM ATP. For each experiment, 2 µl of Get4/5N was injected into Get3 for 20 
intervals spaced 120 sec apart at 25°C. For the first titration, 0.4 µl of Get4/5N was injected. 
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The stirring speed and reference power were 1000 rpm and 5 µcal/s. Affinity constants were 
calculated from the raw data using Origin v7.4 software (MicroCal). 
 
ATPase assay 
Get3 ATPase rates were measured as previously described 41. Briefly, the kcat for 8µM 
Get3 was determined in the presence of excess of ATP doped with (γ-32P) ATP, and analyzed 
by autoradiography. Each Get3 ATPase reaction was conducted in the presence or absence of 
excess (20µM) full-length Get4/5. For Figure 2.4A, individual ratios were calculated for each 
of n independent trials (Supplementary Table 2.1) performed on separate days and then a 
mean and standard deviation were calculated across n ratios. Each independent trial was the 
average of values from two side-by-side reactions. Values used in Supplementary Table 2.1 are 
means and standard deviations calculated across n experiments. 
 
Translocation assay 
The coding sequence for yeast Sbh1 was cloned into a transcription plasmid 34 under 
control of an SP6 promoter and modified as previously described 41. Sbh1 mRNA was 
transcribed using the SP6 Megascript kit (Ambion). All translation and translocation assays 
were performed in yeast as previously described 28 using extracts and microsomes from either a 
Δget3 19 or Δget3/Δget5 34 strain. Get3 translocation efficiency was plotted as a function of 
Get3 concentration and analyzed as previously described 41. 
 
Yeast growth assay  
Knockout strains BY4741 YDL100C::KanMX (Get3) and BY4741 YOR164C::KanMX 
(Get4) were purchased from America Type Culture Collection (ATCC) and used as previously 
described 23,36. The Get3 rescue plasmid was constructed by PCR amplifying the open reading 
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frame with 242 bp upstream and 263 bp downstream flanking regions from BY4741 genomic 
DNA. The Get4 rescue plasmid was constructed by PCR amplifying the open reading frame 
with 233 bp upstream and 86 bp downstream flanking regions from BY4741 genomic DNA. 
Both genes were amplified with SalI and NotI restriction sites and ligated into the pRS316 
vector 58. Mutants were generated by Quikchange site-directed mutagenesis. Yeast strains were 
transformed using the Li/Ac/single-stranded carrier DNA/PEG method 59. Phenotypic rescue 
was determined by growing each transformant in SC-Ura media at 30 °C to an OD600 nm 
between 1 and 2, diluting to 3.85 x 106 cells⁄mL and spotting 4 µL of serial dilutions onto SC -
Ura agar plates in the presence or absence of 2 mM CuSO4. Plates were then incubated at 30 
°C or 40 °C for 24-48 h and photographed. The results were consistent through three trials. 
 
Structure analysis and Figures 
Cartoon representations of protein structures were prepared using PyMol (Schrodinger, 
LLC), while surface representations were prepared using UCSF Chimera 60. Surface figures 
were made in Chimera. Conservation used values for individual residues based on an 
alignment from ClustalW 61. Electrostatic surface potentials were calculated using APBS with 
default values as implemented in the PDB2PQR webserver 62,63. 
 
Accession codes 
Atomic coordinates and structure factors of the Get3D-Get4/5N complex have been 
deposited in the Protein Data Bank under accession code 4PWX. 
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Figures 
Figure 2.1 
 
 
Figure 2.1. Get4/5 prefers ATP-bound state of Get3. 
(A) SEC of Get3D-Get4/5N run in various salt concentrations. (B) SEC of Get3D-Get4/5N in 
250 mM NaCl. (C) Pulldown experiments using 6xHis-tagged Get4/5N and Get3D. The 
amount of Get3D retained after elution is plotted as a fraction of Get4, and error bars represent 
the s.d. from n=3 technical replicates. (D) Summary of the binding affinities of Get4/5N to 
Get3D obtained by ITC experiments. Data is expressed as Kd (µM) with n = at least 3 technical 
replicates. 
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Figure 2.2 
 
 
 
Figure 2.2. 5.4 Å crystal structure of an ATP-bound Get3-Get4/5 complex.  
The asymmetric unit of the Get3D-Get4/5N complex in two orientations (Get4 blue and Get5N 
gray) bound to Get3D (wheat and magenta). Bottom right: Get3D dimer alone in gray to 
emphasize the ‘closed’ structure. ATP is represented as spheres.  
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Figure 2.3 
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Figure 2.3. Get3-Get4 binding interfaces.  
(A) View of the Get3-Get4 interface showing interactions between Get4 (blue) and both 
monomers of Get3D (wheat and purple). Residues at the interface tested for interaction are 
shown as sticks and colored based on phenotype. The positions of side chains cannot be 
determined at this resolution and are only shown here for reference. Below, overview of 
Get3D-Get4/5N in same orientation used to show the interface. Area within the box represents 
the interface shown above. (B) Sequence alignments of regions involved in contacts in the 
Get3-Get4 interface and colored based on ClustalW output 61. Sequences are Scer – S. 
cerevisiae, Afum – Aspergillus fumigatus, Cele – Caenorhabditis elegans, Xlae – Xenopus 
laevis and Hsap – Homo sapiens. Helices are indicated above the sequence and labeled. 
Residues tested are highlighted by spheres and colored based on phenotype (blue, none or 
minimal; orange, moderate; red, strong). (C) Summary of the data obtained by ITC and 
pulldown experiments. Mutants are colored based on strength of phenotype as in (A-B). ITC 
data was generated from a single experiment; pulldown experiments were performed in 
triplicate, with the mean shown.  
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Figure 2.4 
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Figure 2.4. Get4/5 regulates Get3 ATPase activity.  
(A) Get3 ATPase assay in the presence and absence of Get4/5 and mutants. The Get4/5 effect 
is represented as a ratio of kcat in the absence and presence of Get4/5, with a value of 1 
indicating no inhibition by Get4/5. The values are shown as means and standard variations for 
ratios calculated from n independent trials (Supplementary Table 1). (B) Comparison of Get3 
translocation efficiency between wt and K69D. (C) Stereo view of the regulatory interface 
showing interactions between Get4 (blue) and Get3 (purple). (D) Spot plate growth assays of 
pRS316 derived rescue plasmids under control of genetic promoters in the BY4741 
Get3::KanMx or Get4::KanMx background. “KO” represents transformation with empty 
vector. Plates consisted of Sc-Ura with or without 2 mM CuSO4. Each image was taken from a 
single plate at either 24 h (30oC, Sc-Ura) or 48 h (40oC, Sc-Ura w/2 mM CuSO4). 
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Figure 2.5 
 
Figure 2.5. A working model for Get4/5.  
(A) The tetramer of Get3 from the Get3D-Get4/5N crystal lattice in two orientations. Colored 
as in Figure 2B. (B) The tetramer of an archaeal Get3 (PDB ID 3UG6 28) oriented similar to 
(A). (C) A model for the assembly of the Get3-Get4/Get5 tail-anchor binding complex. Colors 
correspond to those in Figure 2 and Figure 5. 
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Tables 
Table 2.1. Data collection and refinement statistics. 
 SSRL BL12-21 
Data collection  
Space group         C 2 
Cell dimensions    
    a, b, c (Å) 166.3, 134.5, 84.1 
    a, b, g  (°)       90, 113.4, 90 
Resolution (Å) 30.0-5.4 (6.0-5.4)2 
Rsym or Rmerge       0.05 (0.46) 
I / sI         7.4 (2.0) 
Completeness (%)       93.8 (95.9) 
Redundancy       0.05 (0.46) 
  
Refinement  
Resolution (Å) 30.0-5.4 (6.0-5.4) 
No. reflections           5,529 
Rwork / Rfree      0.270/0.328 
No. atoms         10,177 
    Protein         10,112 
    Ligand/ion              65 
    Water             n/a 
B-factors     
    Protein           348.5 
    Ligand/ion           317.4 
    Water             n/a 
R.m.s. deviations  
    Bond lengths (Å)          0.0032 
    Bond angles (°)            0.94 
1A single native crystal was used to determine the structure  
of Get3D–Get4–Get5  
2Values in parentheses are for highest-resolution shell. 
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Supplementary Figures 
Supplementary Figure 2.1 
 
0.0 0.5 1.0 1.5
-4
-2
0
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
0.1
0.2
0.3
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
0.0 0.5 1.0 1.5
-10
-8
-6
-4
-2
0
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
0.1
0.2
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
 
0.0 0.5 1.0 1.5
-6
-4
-2
0
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
0.1
0.2
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
0.0 0.5 1.0 1.5
-6
-4
-2
0
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
0.1
0.2
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
0.0 0.5 1.0 1.5
-6
-4
-2
0
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
0.1
0.2
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
0.0 0.5 1.0 1.5
-6
-4
-2
0
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
0.1
0.2
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
0.0 0.5 1.0 1.5
-6
-4
-2
0
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
0.1
0.2
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
0.0 0.5 1.0 1.5
-6
-4
-2
0
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
0.1
0.2
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
0.0 0.5 1.0 1.5
-8
-6
-4
-2
0
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
0.1
0.2
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
0.0 0.5 1.0 1.5
-8
-6
-4
-2
0
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
0.1
0.2
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
0.0 0.5 1.0 1.5
-8
-6
-4
-2
0
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
0.1
0.2
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
0.0 0.5 1.0 1.5
-10
-8
-6
-4
-2
0
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
0.1
0.2
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
0.0 0.5 1.0 1.5
-10
-8
-6
-4
-2
0
-0.6
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
0.1
0.2
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
0.0 0.5 1.0 1.5
-8
-6
-4
-2
0
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
0.1
0.2
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
0.0 0.5 1.0 1.5
-4
-2
0
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
0.1
0.2
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
B
C
Y250A: >10 µME307A: 1.84 µM E253K: >10 µM E304K: >10 µM
K72D: 0.84 µMK69A: 0.76 µM K69D: 0.66 µM K72A: 1.15 µM
D74K: 1.01 µMK15A: 1.19 µM R45A: 0.95 µM Y30A: 3.73 µM
A ADP: 1.57 µM ATP: 0.54 µMapo: >10 µM
Get4-5N:Get3 Molar Ratio Get4-5N:Get3 Molar RatioGet4-5N:Get3 Molar Ratio
Get4-5N:Get3 Molar Ratio Get4-5N:Get3 Molar Ratio Get4-5N:Get3 Molar Ratio Get4-5N:Get3 Molar Ratio
Get4-5N:Get3 Molar Ratio Get4-5N:Get3 Molar Ratio Get4-5N:Get3 Molar Ratio Get4-5N:Get3 Molar Ratio
Get4-5N:Get3 Molar Ratio Get4-5N:Get3 Molar Ratio Get4-5N:Get3 Molar Ratio Get4-5N:Get3 Molar Ratio
  
35 
Supplementary Figure 2.1. Representative ITC isotherms for nucleotide-dependent 
complex formation. (A) Representative measurements for Get3 in various nucleotide states. 
Raw data are shown in the top panel of each trial represented as the power input into the 
sample cell over time. Integrated data are shown in the bottom panels in terms of the total 
energy required for equilibration as a function of the molar ratio of Get4/5N:Get3. The solid 
line represents the best-fit model used to calculate affinities. The affinities indicated for each 
nucleotide state are the average from at least three experiments. In all experiments Get4/5N 
was titrated into the sample cell containing Get3. (B) Representative measurements for Get3 
mutants from the Anchoring interface, top, or the Regulatory interface, bottom. The indicated 
affinity for each mutant represents the value obtained from a single experiment carried out in 
the presence of ATP. (C) Representative measurements for Get4 mutants from the various 
interfaces as in (B). 
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Supplementary Figure 2.2 
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Supplementary Figure 2.2. Surface properties of Get3 and Get4. (A) Left, Surface 
representation of closed Get3 dimer (gray) from (B) showing Get4 binding site (blue), Get1 
cytoplasmic domain binding site (yellow) and the overlap (green). Right: Similar surface 
representation highlighting the Get4 binding site (blue), Get2 cytoplasmic domain binding site 
(red), and the overlap (brown). (B) Left: orientation of Get3 used in subsequent panels to 
highlight the binding interfaces. Monomers are colored as in Figure 2. For surface 
representations one monomer is outlined in black and dashed lines (blue) highlight the 
interaction surface of Get4 on Get3. Center, accessible surface color ramped based on 
electrostatic potential from -12 kT/e (red) to +12 kT/e (blue). Get5N colored gray. Right: 
accessible surface color ramped based on conservation from ≤50% (white) to ≥90% (purple). 
Get5N colored gray. Coloring is based on a ClustalW 34 alignment using the following 
sequences: Saccharomyces cerevisiae, Schizosaccharomyces pombe, Aspergillus fumigatus, 
Candida albicans, Pichia pastoris, Nematostella vectensis, Caenorhabditis elegans, 
Drosophila melanogaster, Danio rerio, Xenopus laevis, Mus musculus, Homo sapiens, 
Arabidopsis thaliana, Neurospora crassa, Anolis carolinensis. (C) Surface properties of Get4 
as in (B), except Get4 is color-ramped from N-terminus (blue) to C-terminus (red). 
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Supplementary Figure 2.3 
 
Supplementary Figure 2.3. Stereo views of the Get3D-Get4/5N interface. (A) The Get3D-
Get4 interface. Coloring is the same as in Figure 3a. Get3 Lys69 and Get4 Asp74 are 
highlighted by open arrowheads. (B) 2FO-FC Electron density contoured at 1.5σ highlighting 
the Get3D-Get4 interface. 
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Supplementary Figure 2.4 
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Supplementary Figure 2.4. TA targeting assay. (A) Representative autoradiograph images 
used to calculate Get3 translocation efficiency corresponding to Figure 4b for wildtype (Top) 
and K69D (Bottom). (B) Comparison of Get3 translocation efficiencies in ∆get3 and 
∆get3/∆mdy2 lysates. (C) Representative autoradiograph images used to calculate Get3 
translocation efficiencies for ∆get3/∆mdy2 lysate in (B). 
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Supplementary Figure 2.5 
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Supplementary Figure 2.5. Tetramers of Get3. A) Tetramers of Get3 seen in various crystal 
forms with Get3 dimers similar to Figure 5A,B. Each is highlighted with the archaeal Get3 
(Methanocaldococcus jannaschii) from PDB ID 3UG6, the Get2-Get3 complex from PDB ID 
3SJD, and the Get3D-Get4/5N crystal structure. (B) Stereo view of the 2Fo-Fc density 
contoured at 1.5σ showing the loops involved in formation of the Get3D-Get4/5N complex 
tetramer. (C) Comparison of the Archaeal MjGet3 dimer aligned to one dimer of the Get3D-
Get4/5N complex dimer. 
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Supplementary Tables 
 
Supplementary Table 2.1. Summary  
of ATPase data 
Get3 
± Get4/5 
kcat (min-1) 
Mean SD1 n 
WT 0.870 0.254 7 + Get4/5 0.139 0.043 
E253K 0.566 0.034 2 + Get4/5 0.536 0.030 
E304K 0.718 0.020 2 + Get4/5 0.739 0.041 
K69A  0.847 
 1 + Get4/5 0.132 
 K69D  1.213 0.298 4 
+ Get4/5 0.508 0.145 
K72A  1.417 
 1 + Get4/5 0.203 
 K72D  1.519 0.078 2 + Get4/5 0.314 0.029 
WT 0.676 0.065 2 +D74K 0.462 0.107 
K69D 1.213 0.298 4 
+D74K 0.135 0.004 2 
1SD = standard deviation; n = number of trials 
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C h a p t e r  3  
MOLECULAR DETAILS OF A GET3-GET4/GET5 INTERMEDIATE COMPLEX 
 
 
Abstract 
  
Tail-anchored (TA) proteins, defined as having a single transmembrane helix at their C-
terminus, are post-translationally targeted to the endoplasmic reticulum (ER) membrane by the 
GET (Guided Entry of TA proteins) pathway. In the yeast pathway, the handover of TA 
substrates is mediated by the heterotetrameric Get4/Get5 (Get4/5) complex, which tethers the 
co-chaperone Sgt2 to the targeting factor, the Get3 ATPase. Binding of Get4/5 to Get3 is 
critical for efficient TA targeting; however, questions remain about the formation of the Get3-
Get4/5 complex. Here we report crystal structures of a Get3-Get4/5 complex from 
Saccharomyces cerevisiae (Sc) at 2.8 Å and 6.0 Å, which reveal a novel interface between 
Get3 and Get4 dominated by electrostatic interactions. Kinetic and mutational analyses 
strongly suggest that these structures represent an on-pathway intermediate that rapidly 
assembles and then rearranges to the final Get3-Get4/5 complex. Furthermore, we provide 
evidence that the Get3-Get4/5 complex is dominated by a single Get4/5 heterotetramer bound 
to one monomer of a Get3 dimer, uncovering an intriguing asymmetry in the Get4/5 
heterotetramer upon Get3 binding.  Ultrafast electrostatically driven Get3-Get4/5 association 
enables Get4/5 to rapidly sample and capture Get3 at different stages of the GET pathway. 
 
 
Adapted from 
Gristick, H.B., Rome, M. E., Chartron, J. W., Rao, M., Hess, S., Shan, S. O., and Clemons, 
W.M., Jr. Molecular details of a Get3-Get4/Get5 intermediate complex. In Submission. 
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Introduction 
The targeting of membrane proteins to their correct location in the cell is a highly 
regulated process 44. The majority of membrane proteins are targeted via the signal recognition 
particle (SRP), which typically recognizes the initial hydrophobic transmembrane domain 
(TMD) as it emerges from the ribosome 3. However, the ubiquitous TA proteins, defined 
topologically by a single TMD near the C-terminus, are unable to access the SRP pathway as 
their targeting signal, the single TMD, emerges from the ribosome only after protein synthesis 
is complete and must be targeted to the ER post-translationally 8,9. In eukaryotes, TA proteins 
account for at least 1% of the proteome, and are involved in many essential cellular processes 
such as apoptosis, vesicle fusion, and protein trafficking 45,46. 
A series of genetic and biochemical experiments in yeast and mammalian cells 
identified members of a dedicated pathway for delivery of TA-proteins to the ER. In yeast, 
these factors compose the Guided Entry of TA proteins (GET) pathway that consists of six 
proteins, Get1-5 and Sgt2, all with homologs in higher eukaryotes 47,64. The first committed 
step in TA targeting is the formation of an Sgt2/TA complex 34, which may be assisted by 
chaperones. TA substrate is transferred to Get3 in a Get4/5-dependent manner 34. Extensive 
structural characterization of Get3, the central TA targeting factor, demonstrated that it 
undergoes ATP-dependent conformational changes from an open to closed form required for 
capturing the TA substrate 23-28. Once formed, this Get3-TA complex is then localized to the 
ER by the membrane proteins Get1/Get2 (Get1/2), which stimulate release of the TA protein 
and subsequent insertion into the ER membrane 29-32.  
Efficient delivery of a TA substrate to Get3 requires the hetero-tetrameric Get4/5 
complex that provides the link between Sgt2 and Get3 21,22,34. Get4/5 stabilizes the ATP-bound 
state of Get3 delaying ATP release and inhibiting ATP hydrolysis, thereby locking Get3 in a 
conformation competent for TA substrate binding 41. Recently, the first crystal structure of a 
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Get3-Get4/5 complex provided insight into the role of nucleotide in complex formation, where 
Get4 binds to two functionally distinct binding interfaces, anchoring and ATPase regulation, on 
a closed Get3 65. Importantly, mutations introduced at these interfaces demonstrated that Get4-
mediated regulation of ATP hydrolysis by Get3 were critical for efficient TA targeting. A 
recent study has now shown that Get4/5 binding to Get3 occurs in very rapid diffusion-limited 
timescales, suggesting an electrostatic interaction 43 However, the nature of this interaction 
cannot be explained by the aforementioned Get3-Get4/5 structure. 
This report describes the crystal structure of a Get3-Get4/5N intermediate complex 
from Saccharomyces cerevisiae (Sc) in two crystal forms, at 2.8 Å and 6.0 Å respectively. The 
structure represents an initial binding interaction mediated by electrostatics that facilitates the 
rate of subsequent inhibited complex formation. This is supported by kinetic analysis of Get3-
Get4/5 complex formation confirming the two-step complex formation. Finally, mass 
spectrometry and multi-angle light scattering are used to demonstrate that, under physiological 
steady-state conditions, a single Get4/5 heterotetramer is bound to one monomer of an empty 
Get3 dimer. This work allows us to generate a refined model for Get3-Get4/5 complex 
formation. 
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Results 
Formation of the Get3-Get4/5 complex follows an electrostatically-driven intermediate 
To understand the mechanism of assembly for the Get3-Get4/5 complex, we 
characterized the assembly pathway using pre-steady-state kinetics.  Complex formation was 
monitored using acrylodan labeled Get4/5, whose fluorescence is enhanced upon binding Get3 
43. The Get3-Get4/5 complex has been demonstrated to be highly stable yet dynamic, and its 
formation follows rapid biphasic association at near diffusion-limited timescales 43. The 
observed association rate constants in both kinetic phases are linearly dependent on Get3 
concentration 43, indicating that both phases represent bi-molecular association of Get3 with 
Get4/5. While the initial report used full-length Get4/5, the same biphasic association was 
observed with a truncated Get4/5N that lacks the homodimerization domain of Get5 and hence 
forms a heterodimer (Figure 3.1A-B). This rules out the possibility that the second kinetic 
phase arises from binding of Get3 to the second Get4 molecule in a Get4/5 heterotetramer.   
Additional characterizations strongly suggest the presence of an additional 
rearrangement step in the assembly pathway. First, the rate of the initial “burst” phase is 
strongly dependent on ionic strength consistent with electrostatically-driven association 43 
(Figure 3.1C), whereas the second association phase is independent of ionic strength 43 
(Figure 3.1D). This suggests a structural rearrangement to adopt a more stable interface prior 
to the second association phase. Secondly, despite the large changes in the relative association 
rates of the salt-sensitive and -insensitive phases, the amplitudes of these two phases are 
unaltered by changes in ionic strength (Figure 3.1E). This argues against the possibility that 
the biphasic association arises from parallel pathways, i.e., that the second association phase 
arises from a sub-population of Get3 (or Get4/5) that binds the interaction partner with slower 
kinetics. Thirdly, the dissociation rate constant extrapolated from the fast association phase 
(Figure 3.1B) is 8–10 s-1 (kobsd = kon[Get3] + koff); this koff value is 10–100 fold faster than those 
  
48 
of the final Get3-Get4/5 complex determined directly in pulse-chase experiments 43 (Figure 
3.1F), suggesting that the initial association gives rise to an unstable intermediate that must 
subsequently rearrange to adopt more stable interfaces. Further in support of this model are 
results from the dissociation rate measurements. While dissociation of the Get3-Get4/5 
complex also exhibits biphasic kinetics, neither the rates nor the magnitude of the phases are 
dependent on ionic strength (Figure 3.1F).  Finally, the magnitude of the slow dissociation 
phase increases successively when apo-Get3 is compared with ADP- and ATP-bound Get3 
(Figure 3.1G), consistent with previous data showing that ATP strengthens binding between 
Get3 and Get4/5 by inducing Get3 into a more closed conformation 36,41,43,55,65.  
These new data, coupled with kinetic simulation, support a multi-step mechanism for 
the Get3-Get4/5 interaction as the simplest model to explain all the available observations 
(Figure 3.1H) 43. In this model, association of Get3 with Get4/5 involves the following steps: 
(i) resting Get3 bound to ATP is biased towards a ‘closed’ conformation; (ii) initial binding of 
Get4/5 to Get3 is rapid and generates an intermediate dominated by electrostatic interactions; 
(iii) this is followed by a conformational change to the final stable structure dominated by 
hydrophobic interactions; (iv) under the experimental conditions, the second subunit in the 
Get3 dimer can bind another Get4/5 complex to give rise to the second phase in association 
kinetics  Using the experimentally observed kon and koff values from both the salt-sensitive and 
salt-insensitive phases, the equilibrium binding data and kinetic modeling, we were able to 
completely assign the rate constant for individual microscopic steps in this model.  Analytical 
simulations based on this model reproduced the experimentally observed 
association/dissociation kinetics and equilibrium titrations (Figure 3.2A). Furthermore, the 
equilibrium titration data with full-length Get4/5 43 could only be fit to a 1:2 stoichiometry in 
which a Get3 dimer is bound to two different Get4/5 heterotetramers (Figure 3.2B), consistent 
with the biphasic nature of complex formation.  
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Although binding of a second Get4/5 complex to Get3 was observed (Figure 3.1H), 
multiple observations suggest that the stable Get3-Get4/5 complex (species (ii)) dominates 
under most conditions and accumulation of the saturated Get3-Get4/5 complex is modest. First, 
previous assays of Get3 activity show that binding of one full-length Get4/5 complex is 
sufficient to inhibit Get3’s ATPase reaction 41.  Second, kinetic simulations show that during 
complex assembly with relatively stoichiometric amounts of proteins, the saturated Get3-
Get4/5 complex accumulates to <20% of all the complexes formed (Figure 3.2C). Coupled 
with the different Get3-Get4/5N complexes in various crystal structures 65, it appears that 
binding of Get4/5 to Get3 has a preferred, but not obligatory, stoichiometry.  
 
The structure of a Get3-Get4/5 intermediate complex 
The recent crystal structure of an ATP-bound Get3-Get4/5N complex demonstrated a 
stable interface that included conserved hydrophobic interactions 65. The structure allowed 
rationalization of how Get4 stabilized an ATP-bound Get3; however, it was unclear how the 
structure could account for the multi-step Get3-Get4/5 assembly seen experimentally. To 
address this question, we set out to obtain a structure of Get4/5N bound to a Get3 dimer under 
conditions that would stabilize an initial intermediate complex. As before 65, Get3 and Get4/5 
were expressed and purified separately, and then combined and purified as a 1:1 complex in 
low ionic strength conditions over size-exclusion chromatography (SEC) (Figure 3.3). Initial 
crystals were obtained using a Get4/5N construct similar to that used for solving the structure 
of the Get4/5N heterodimer 36. This resulted in a crystal that diffracted to 6.0 Å in space group 
P21. Phases for this crystal form were obtained by molecular replacement using an “open” form 
of Get3 (3A37) 27 and the Get4/5N heterodimer (3LKU) as search models. The final model was 
refined to an R/R-free of 27.4/30.3% (Table 1). To improve the diffraction limit, purification 
and crystallization trials were performed in the presence of either ADP or the non-hydrolyzable 
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ATP-analogue AMP-PNP. In addition, 22 residues from the C-terminus of Get4 were 
truncated, as they were disordered in previous structures 25,36. This resulted in a new crystal 
form that diffracted to 2.8 Å in space group P21212. The final model was refined to an R/R-free 
of 22.4/26.1% (Table 1). 
 
The Get3-Get4/5 intermediate complex is dominated by an electrostatic interface 
In both crystal forms, Get4 binds in a similar orientation on Get3 (Figure 3.4A-B). The 
2.8 Å structure contains a 2:1 complex of a Get3 dimer bound to a single Get4/5N heterodimer 
(Figure 3.4A). This crystal form is related to another Get3 crystal form 27 in which limited 
space in the crystal lattice allows for only one Get4/5N molecule (Figure 3.4C) despite the 1:1 
stoichiometry of the complex put into crystallization trays as measured by SEC (Figure 3.3). 
While nucleotide was present throughout purification and crystallization, the nucleotide-
binding pocket appears empty. For the 6.0 Å structure (Figure 3.4B), the asymmetric unit 
contained a 1:1 complex with 8 copies of Get3 bound to 8 Get4/5N heterodimers (Figure 
3.4B). 
In both cases, Get3 is in an ‘open’ conformation, and Get4/5N binds in the same 
interface and orientation, defined here as the intermediate complex. Despite the differences in 
crystallization and space group, there is little difference in the interface between the two 
structures, with only a slight 10° rotation at the furthest point (Figure 3.4D). The higher 
resolution structure will be used for reference for the rest of the text. In this intermediate 
complex, Get4 interacts with a single monomer of Get3 in an orientation compatible with both 
the ‘open’ and ‘closed’ structures, burying ~970 Å2 of surface area (Figure 3.5A-B). The 
interactions in this interface are electrostatic and involve the positive face of Get4 binding to 
the negative surface of Get3 (Figure 3.5A-B). 
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In this orientation, Get4 α1 sits on top of a groove formed by the loop before Get3 α1 
and the loop following Get3 α11, such that the N-terminus of Get4 α1 packs against the loops 
following Get3 α9 and α10, resulting in an interaction between K23 on Get4 α1 and E307 on 
Get3 (Figure 3.5C). In addition, Get4 α2 packs roughly perpendicular to Get3 α10 and α11, 
such that the N-terminus contacts Get3 α11 and the C-terminus contacts Get3 α10. This results 
in interactions between the invariant residues R42 on Get4 α2 and D308 on Get3, and R45 on 
Get4 α2 with both E253 and Q257 on Get3 α10 (Figure 3.5C). Finally, the N-terminus of Get4 
α3, which is oriented between α1 and α2, contacts the top of Get3 α10, allowing H51 on Get4 
α3 to contact D263 on Get3 α10 (Figure 3.5C). 
 
Comparison of the two distinct Get3-Get4/5 complexes 
In the previously reported ATP-bound Get3-Get4/5N complex Get4/5N is bound across 
the dimer interface of a “closed” Get3, forming interactions with both monomers, which we 
define as the inhibited complex (Figure 3.6). This is in contrast to the current structure, which 
is bound to an “open” Get3 and interacts with only one monomer (Figure 3.6). Since the Get4-
binding surfaces do not undergo a conformational change between the “open” and “closed” 
Get3 structures, we aligned the helices (α10 and α11) involved in Get4 binding from our 
intermediate complex onto the inhibited complex. Both structures have overlapping binding 
sites and predominantly utilize the N-terminus of Get4 for the interaction (Figure 3.6). The 
difference in orientation involves a rotation centered on the 2nd helix of Get4. This rotation 
allows Get4 α2 to form the majority of the interactions in the inhibited complex, whereas Get4 
α1 is responsible for the majority of the interactions in the intermediate complex. Based on the 
multi-step assembly observed from kinetic analysis, we believe that the new structure 
dominated by electrostatics represents the intermediate Get3-Get4/5 complex (Figure 3.1H, 
species (ii)) prior to rearrangement to the final structure stabilized by hydrophobic interactions.   
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Mutational analysis of the intermediate complex 
The intermediate complex interface involves numerous electrostatic residues on both 
Get3 and Get4. Of these interactions, only Get3 D263-Get4 H51 and Get3 E307-Get4 K23 are 
unique to the intermediate interface and are not found in the stable complex (Figure 3.7A). 
The first interaction (D263-H51) is not conserved; however, in higher eukaryotes there is 
conservation of a likely salt bridge (Figure 3.7A). The conserved Get3 E307 also interacts with 
the cytoplasmic domain of Get2 29,30, whereas Get4 K23 is not conserved (Figure 3.7A). 
Substitution of Get3 D263 leads to a loss of observable binding to Get4/5N, as measured by 
ITC (Figure 3.7B), whereas substitution of Get3 E307 had a more modest loss in affinity 
(Figure 3.7B).  
If the intermediate complex is on-pathway to the final Get3-Get4/5 complex, one would 
predict that disrupting the interactions unique to this intermediate would slow down Get3-
Get4/5 association. Disrupting the putative Get3 E307-Get4 K23 interaction (E307A) resulted 
in similar association rates compared to wildtype Get3 and, together with the ITC results, 
suggests that the interaction is not essential for complex formation (Figure 3.7B-C). In 
contrast, significantly reduced rates of Get3-Get4/5 association were observed with Get3 
D263A (Figure 3.7B-C). While the association rates are slightly higher than previously 
reported, the differences are small (~2-fold) and do not change the interpretation. Both mutants 
had virtually identical dissociation rates compared to wildtype Get3; therefore, the difference in 
affinity for D263A is specific for complex formation kinetics (Figure 3.7B-C).  
If Get3 D263A follows the same assembly pathway as wildtype Get3, one would 
expect that once the Get3(D263A)-Get4/5 complex is formed, it has the same equilibrium 
stability as the wildtype complex since D263 does not form any interactions in the final 
complex (Figure 3.7D). However, the weakened equilibrium stability of the Get3(D263A)-
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Get4/5 complex indicates that the changes induced by D263A are more complex, and this 
mutant likely follows a different assembly pathway leading to a non-native complex. Since a 
reaction follows the fastest pathway, this observation in turn suggests that the D263A mutation 
slows the native assembly pathway more extensively than was experimentally measured.  
Collectively, mutational analysis of the intermediate complex provides independent evidence 
that the structure observed here represents an on-pathway intermediate during Get3-Get4/5 
assembly.  
 
Stoichiometry between Get3 and Get4/5  
The stoichiometry of the Get3-Get4/5 interaction is not fully understood. A recent 
SEC-MALLS analysis using an ATPase deficient Get3 (D57N) suggested that the complex 
contains one Get4/5 heterotetramer bound to one Get3 dimer 66. Using wildtype Get3, SEC-
MALLS analysis using equimolar concentrations of Get3 and Get4/5 confirmed that the size of 
the complex is consistent with a single Get4/5 heterotetramer bound to a single Get3 dimer 
(Figure 3.8A).  
One puzzling observation arises from this data: despite the presence of two Get4 
molecules in full-length Get4/5, there has been no evidence for binding of Get3 to the second 
Get4 in the Get4/5 heterotetramer. To directly test this asymmetry of Get4/5 during complex 
formation, we developed an alkylation-protection assay. An engineered cysteine at the Get3-
Get4/5 interface (Get4 S48C 43) is allowed to react with N-ethyl-maleimide (NEM) in the 
absence and presence of various factors (Figure 3.8B). In the free Get4/5 complex, Get4 C48 
is solvent exposed 36 and rapidly alkylates to completion (Figure 3.8B-C). If both copies of 
Get4 in the Get4/5 complex can bind Get3, S48C should be rendered solvent inaccessible and 
be completely protected from alkylation (Figure 3.8B). Consistent with binding at a single 
Get4 interface, only 50% of Get4 C48 was protected from alkylation by Get3 (Figure 3.8C). 
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This protection pattern was observed at Get3 concentrations nearly 1000-fold above the 
dissociation constant for the Get3-Get4/5 complex, indicating that the 50% protection did not 
arise from incomplete Get3-Get4/5 binding. These results strongly suggest that only one site of 
a Get4/5 heterotetramer is able to bind Get3.  
To further support these results, accessibility of Get4/5 was probed using a 10kDa 
PEG-maleimide label. A second site was chosen to further validate the interface (Get4 Q34C) 
that is also occluded in the Get3-Get4/5N structure (Figure 3.8D). Importantly, substitution of 
Q34 to alanine does not impair binding to Get3 65. In this reaction, Get4 Q34C with PEG-
maleimide forms a covalent adduct that gives a 10kDa increase in mass, which can be detected 
by SDS-PAGE and Coomassie staining (Figure 3.8E). In the absence of Get3, this reaction 
resulted in 100% pegylation of Get4/5 over a two-minute time course, whereas addition of 
saturating Get3 resulted in 50% pegylation (Figure 3.8E). This provides corroborating 
evidence that only one Get4 molecule in a heterotetramer binds Get3.  Together, these data 
indicate that once Get3 binds to Get4/5, the other Get4 molecule in the Get4/5 heterotetramer is 
inhibited from further interaction with another Get3 dimer.   
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Discussion 
A model for Get3-Get4/5 complex formation 
Multiple lines of evidence support a model in which Get3 and Get4/5 rapidly form an 
electrostatic intermediate complex, and then undergo a structural rearrangement to a more 
stable complex 43 (Figure 3.2A). This conformational change is consistent with previous 
results showing that Get4/5 binding induces Get3 into an “occluded” state, leading to Get3 
ATPase inhibition and delayed ATP dissociation kinetics 41. Based on this model, once Get3 
has transitioned to the occluded conformation, complex dissociation would be insensitive to 
buffer ionic strength (Figure 3.1F) but nucleotide-dependent (Figure 3.1G). 
The new crystal structures of the Get3-Get4/5 complex presented here (Figure 3.2A-B) 
reveal a novel-binding interface composed of electrostatic interactions (Figure 3.5).  These 
structures provide the molecular basis for the initial, salt-dependent association seen in our 
kinetic description of the Get3-Get4/5 interaction (Figure 3.1). This is corroborated by the 
D263A mutation introduced within this interface, which drastically slows down complex 
formation (Figure 3.7). These data coupled with the kinetic experiments argue that these 
structures represent the initial intermediate complex between Get3 and Get4/5. 
As we previously reported, Get4/5 is able to precisely discriminate between nucleotide 
states of Get3, enabling Get4/5 to regulate Get3 activity and prime it for efficient capture of the 
TA substrate 41,43,65. The structure described here provides evidence for an additional 
interaction dominated by electrostatic interactions and characterized by fast association rates. 
This ultrafast diffusion-limited association of Get4/5 to Get3 43 may function as an additional 
mechanism for Get4/5 to select for the appropriate conformational state of Get3, or inversely, 
enables Get3 to constantly sample Get4/5 complexes until transfer of TA substrate occurs. 
Interestingly, this may also function to ensure Get3 is quickly recruited following dissociation 
from the membrane to prevent re-binding to Get1 or Get2 43. This type of interaction has been 
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seen in other systems including barnase-barstar 67 and ribosome interacting proteins 68, and 
likely represents a recurring theme in protein-protein interactions. This work provides further 
evidence for the importance of Get4/5 in TA targeting. 
 
  
57 
Acknowledgements 
We thank Graeme Card, Ana Gonzalez and Michael Soltis for help with data collection 
at SSRL BL12-2. We are grateful to Gordon and Betty Moore for support of the Molecular 
Observatory at Caltech. The PEL (S.H.) was supported by the Gordon and Betty Moore 
Foundation, through Grant GBMF775 and the Beckman Institute. Operations at SSRL are 
supported by the US DOE and NIH. This work was supported by career awards from the David 
and Lucile Packard Foundation and the Henry Dreyfus Foundation (S.-o.S.), NSF Graduate 
Research Fellowship DGE-1144469 (M.E.R.), NIH training grant 5T32GM007616-33 (H.G. 
and M.R.) and NIH research grant R01GM097572 (W.M.C.).  
 
  
58 
Methods 
Protein cloning, expression, and purification 
The sequences of Get4 and Get5 were cloned as previously described 36. To generate 
the Get4/5N used in this study, this construct was further modified by truncating the C-
terminus of Get4 (residues 291-312), and by the addition of a stop codon after residue 54 
within Get5, and verified by DNA sequencing. All Get4/5 proteins were overexpressed in 
BL21-Gold (DE3) (Novagen) grown in 2xYT media at 37 °C and induced for 3h by the 
addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). Cells were lysed using a 
microfluidizer (Microfluidics) and purified as a complex by Ni-affinity chromatography 
(Qiagen). The affinity tag was removed by an overnight TEV protease digest at room 
temperature while dialyzing against 20 mM Tris pH 7.5, 30 mM NaCl, and 5 mM β-
mercaptoethanol (BME). A second Ni-NTA column was used to remove any remaining his-
tagged protein, and the sample was then loaded onto a 6 mL Resource Q anion exchange 
column (GE Healthcare). The peak containing the Get4/5N complex was collected and 
concentrated to 15-20 mg/mL. Initial purifications of the Get4/5N complex were verified to be 
a single monodispersed species over SEC using a Superdex 200 16/60 column (GE Healthcare) 
equilibrated with 20 mM Tris pH 7.5, 100 mM NaCl, and 5 mM BME. Full-length Get4/5 used 
in ATPase assays and translocation experiments was further purified using a Superdex 200 
16/60 column (GE Healthcare) equilibrated with 20 mM K-HEPES pH 7.5, 150 mM KOAc, 10 
mM MgOAc, 10% (v/v) Glycerol, and 5 mM BME. Fractions containing Get4/5 were pooled 
and concentrated to ~5 mg/mL. 
The S. cerevisiae Get3 coding region was cloned as previously described 23. A 6xHis-
tag followed by a tobacco etch virus (TEV) protease site was fused to the N-terminus, and a 
stop codon was placed in front of the C-terminal 6xHis-tag. All S. cerevisiae Get3 mutants 
were generated using the QuikChange method. All Get3 proteins were made in BL21-
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Gold(DE3), grown in 2xYT media, and induced with 0.5 mM IPTG for 16h at 22oC. Cells 
were lysed using a microfluidizer (Microfluidics) and purified by Ni-affinity chromatography 
(Qiagen). The affinity tag was removed by an overnight TEV protease digest at room 
temperature while dialyzing against 20 mM Tris pH 7.5, 100 mM NaCl, and 5 mM BME. A 
second Ni-NTA column was used to remove any remaining his-tagged protein, and the sample 
was run on a Superdex 200 16/60 column (GE Healthcare) equilibrated with the dialysis buffer. 
Fractions corresponding to a dimer of Get3 were pooled and concentrated to 15-20 mg/mL. 
Get3 derivatives used for ATPase assays and translocation experiments were further purified 
over a MonoQ anion exchange column to remove contaminating ATPases. 
Get3-Get4/5N complex was formed by equilibrating 105 µmol Get4/5N with 100 µmol 
Get3 at room temperature in 500 µL of 20mM Tris pH 7.5, 10mM NaCl, 5mM BME, 1mM 
MgCl2, and 1mM of either ADP, AMP-PNP, or ATP. Prior to complex formation, Get3 had 
been pre-equilibrated with 1mM MgCl2 and either 1mM ADP or 1mM AMP-PNP for 5min at 
room temperature. Get3-Get4/5N complex was further separated from free Get4/5N using a 
Superdex 200 10/300 (GE Healthcare) equilibrated with 20 mM Tris pH 7.5, 10 mM NaCl, and 
5 mM BME. Get3-Get4/5N complex using full-length Get4 was formed as above but in the 
absence of nucleotide and MgCl2. This complex was further separated from free Get4/5N using 
a Superdex 200 16/60 (GE Healthcare) equilibrated with 20 mM Tris pH 7.5, 10 mM NaCl and 
5 mM BME. All complexes were concentrated to 10-12 mg/mL before use in crystallization 
experiments. 
 
Crystallization 
Purified Get3-Get4/5N complex was concentrated to 10-12 mg/ml and crystal trials 
were carried out using the sitting-drop vapor diffusion method at room temperature by 
equilibrating equal volumes of the protein complex solution and reservoir solution using a TTP 
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LabTech Mosquito robot and commercially purchased kits (Hampton Research, Qiagen, 
Molecular Dimensions Limited). The 2.8 Å Get3-Get4/5N OC crystals grew in the presence of 
17% PEG 3350, 0.24 M Na citrate, and 30 mM TCEP. Crystals were cryoprotected by 
transferring directly to 10µL of a reservoir solution supplemented with 20% glycerol, 1mM 
ADP or AMP-PNP, and 1 mM MgCl2 and incubated for ≥10 min before being flash frozen in 
liquid nitrogen. The 6.0 Å Get3-Get4/5N OC crystals grew in the presence of 12% PEG 3350 
and 0.1 M Na malonate (pH 5.0), and were cryoprotected by transferring directly to 10µL of a 
reservoir solution supplemented with 20% glycerol before being flash frozen in liquid nitrogen. 
 
Data collection, structure solution, and refinement 
All structures were solved using datasets collected on Beamline 12-2 at the Stanford 
Synchrotron Radiation Lightsource (SSRL). Each structure was solved from a single dataset 
that was integrated using MOSFLM 50 or XDS 51, and scaled and merged using SCALA 52,53. 
Crystal of Get3-Get4/5N in the OC conformation diffracted to 2.8 Å and was solved by 
molecular replacement with PHASER 54 as implemented in PHENIX 55, using a monomer of 
the open (apo) form of Get3 (PDB ID 3A37) and one Get4/5N heterodimer (PDB ID 3LKU) as 
search models. No solution was found using the closed (ADP-AlF4) form of Get3 (2WOJ). 
Coordinates were refined using REFMAC v6.3 52,53 with NCS and B-factor restraints. Manual 
rebuilding was performed using COOT 57. TLS groups were included in the later refinement 
stages and were determined using the TLSMD web server 69. These associated regions within 
the structure were allowed a certain degree of variation based on predicted motions they might 
have during data collection. The final model refined to an R-factor of 22.4% (Rfree = 26.1%). 
The second structure in the OC conformation was solved to 6.0 Å using methods similar to 
those described above. This structure lacked the Get4 C-terminal truncation engineered for the 
other structures and refined to an R-factor of 27.4% (Rfree = 30.3%). Full statistics in Table 3.1. 
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Structure analysis and Figures 
Cartoon representations of protein structures were prepared using PyMol (Schrodinger, 
LLC), while surface representations were prepared using UCSF Chimera 60. Surface figures 
were made in Chimera. Conservation used values for individual residues based on an 
alignment from ClustalW 61. Electrostatic surface potentials were calculated using APBS with 
default values as implemented in the PDB2PQR webserver 62,63. 
 
Isothermal titration calorimetry 
Get3(D57V)-Get4/5N binding experiments were carried out using the MicroCal 
iTC200 system (GE Healthcare). Binding affinities were measured by filling the sample cell 
with 50 µM Get3D and titrating 350 µM Get4/5N. The buffer conditions were identical for all 
samples and contained 50 mM K-HEPES pH 7.5, 150 mM KOAc, 10 mM MgOAc, 10% (v/v) 
Glycerol, and 1mM ATP. For each experiment, 2 µl of Get4/5N was injected into Get3 for 20 
intervals spaced 120 sec apart at 25°C. For the first titration, 0.4 µl of Get4/5N was injected. 
The stirring speed and reference power were 1000 rpm and 5 µcal/s. Affinity constants were 
calculated from the raw data using Origin v7.4 software (MicroCal). 
 
Multi Angle Light Scattering 
100 µL of 35 µM Get3 and 100 µL of 35 µM Get4/5 diluted in 50 mM K-HEPES pH 
7.5, 150 mM KOAc, 10 mM MgOAc, 10% (v/v) Glycerol, 5 mM BME, and 2 mM ATP were 
either loaded separately or together onto a Superdex 200 10/300 (GE Healthcare) column 
equilibrated in the above buffer. All protein concentrations were 35 µM. Samples were 
analyzed using a Dawn HELEOS II multi-angle light scattering unit (Wyatt Technology). 
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Alkylation and Mass Spectrometry 
Cysteine mutants of Get4/5 were reduced with 2.5 mM TCEP at RT for 2 h, followed 
by the addition of 100 µM NEM. The reaction was quenched with 50 mM DTT at various time 
points, concentrated under vacuum, redissolved in 0.2% formic acid, and 25 pmol protein was 
analyzed on an LC-MSD SL 1100 series (Agilent). The samples were chromatographed on a 
2.1 x 150 mm Zorbax 300SB-C3 column (Agilent) using a gradient consistent of 0.2% formic 
acid and 0.2% formic acid in acetonitrile (89.8%) and methanol (10%). The m/z of the intact 
proteins were measured in the single quadrupole, deconvoluted, and quantified using the 
ChemStation software (Agilent). Control experiments, where different ratios of un-alkylated 
and alkylated proteins were mixed and subjected to MS analysis, showed the quantification of 
ratio of alkylated species to be reliable 70. 
 
Get4/5 PEGylation Assay 
Get4/5 Q34C/C177T containing a 6xHIS tag was reduced with 2.5 mM TCEP in Get 
buffer (without DTT) at RT for 2 hours. For each PEGylation reaction, 0.45 µM Get4/5 alone 
or in the presence of 2 µM Get3 was pre-incubated in 2mM ATP for 10 minutes to allow for 
complex formation, followed by the addition of 60 µM PEG-maleimide (10,000 Da Mw 
conjugates, SIGMA). The reaction was quenched with 9.0 mM DTT at the indicated time 
points, and the extent of Get4/5 PEGylation was followed by Western Blot with an anti-HIS 
antibody (Qiagen). The ratio of un-modified Get4/5 to PEGylated Get4/5 was determined using 
ImageQuant software (GE Healthcare). 
 
Fluorescent labeling 
Get4/5 S48C/C177T and Get4/5N S48C/C177T were labeled with thiol-reactive 
acrylodan. Protein was dialyzed in labeling buffer (50 mM KHepes, pH 7.0, 300 mM NaCl) 
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and treated with 2 mM TCEP to reduce the disulfide bonds. The labeling reaction was carried 
out using a 10-30 fold excess of dye over protein. The reaction was incubated overnight at 4 °C 
and stopped by adding 2 mM DTT. Excess dye was removed by gel filtration using Sephadex 
G-25 (Sigma) equilibrated with GET buffer. 
 
Association and Dissociation rate measurements 
All rate measurements were performed on a Kintek stopped-flow apparatus. For 
association rate measurements, acrylodan-labeled Get4/5 was held constant at 0.2 μM, Get3 
concentration was varied as indicated, and ATP was present at 2 mM. Observed rate constants 
(kobsd) were plotted as a function of Get3 concentration and fit to the following equation (Eq. 1),  
kobsd = kon[Get3] + koff     (1) 
in which kon is the association rate constant, and koff is the dissociation rate constant.  
For dissociation rate measurements, a pulse-chase experiment was used. A complex between 
acrylodan-labeled Get4/5 (at 0.15 μM) and Get3 (at 0.3 μM) was preformed by incubation in 2 
mM ATP for 10 minutes, followed by addition of unlabeled Get4/5 at 6 μM as the chase to 
initiate Get3-Get4/5 dissociation. The time course for change in fluorescence (Fobsd) was fit to 
the following double exponential function (Eq. 2),  
                                  Fobsd = Fe  + ΔF1 × e–kfastt + ΔF2 × e–kslowt                                                                               (2) 
in which Fe is the fluorescence when the reaction reaches equilibrium, ΔF1 and kfast are the 
magnitude and rate constant of the fluorescence change in the fast phase, and ΔF2 and kslow are 
the magnitude and rate constant of the fluorescence change in the slow phase. 
 
Kinetic Modeling 
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The kinetic model was derived using KinTek Explorer Professional Software (Kintek 
Corporation) 71,72. Kinetic and equilibrium simulations were carried out using the rate constants 
and theoretical protein concentrations listed in Figure 1. 
 
Accession codes 
Atomic coordinates and structure factors of the Get3-Get4/5N intermediate complexes 
have been deposited in the Protein Data Bank under accession codes 5BW8 (2.8 Å) and 5BWK 
(6.0 Å). 
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Figures 
Figure 3.1 
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Figure 3.1. Get4/5 undergoes a conformational change upon binding Get3.  
(A) Time course of Get4/5N binding to ATP-bound Get3. Arrows indicate the two kinetic 
phases. (B) Observed association rate constants (kobsd) are analyzed as a function of Get3 
concentration to determine the association rate constant kon for both the first (circles) and 
second (triangles) kinetic phases. (C) Plots Get3-Get4/5N association rates are highly salt-
sensitive. (D) Summary of association rate constants in different salt concentrations for the 2nd 
kinetic phase in Get3-Get4/5 ON rate measurements. (E) The amplitude of the 1st kinetic phase 
for Get3-Get4/5 association in different salt concentrations is invariant to buffer ionic strength. 
(F) Dissociation rate measurement of Get3 from Get4/5 in 350mM NaCl (red) and no salt 
(blue). (G) Percent amplitude of the 2nd kinetic phase for Get3 dissociation from Get4/5N in 
different nucleotide states. (H) Proposed Model for Get3-Get4/5 complex association based on 
kinetic data. 
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Figure 3.2 
 
Figure 3.2. Modeling of experimental kinetic data. 
(A) Comparison of experimental (black) and theoretical (red) binding data for the Get3-Get4/5 
complex. Association rate measurements (left), dissociation rate measurements (center), 
equilibrium titrations (right). All values reported in Table 3.2. (B) Left, model depicting a 1:2 
binding stoichiometry of Get3 with Get4/5. This configuration was used to fit an equilibrium 
titration of ACR-labeled Get4/5-FL (100 nM) with Get3 in 2mM ATP. Right, same as on left 
but with a 1:1 binding stoichiometry. (C) Berkeley Madonna simulation of Get3-Get4/5 
complex formation. 
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Figure 3.3 
 
Figure 3.3. Purification of the Get3-Get4/5N complex.  
Left, SEC of Get3/Get4/5N over a Superdex 16/60 column in the absence of nucleotide. 
Center, SEC of Get3/Get4∆C/5N over a Superdex 10/300 column in the presence of ADP. 
Right, SDS-PAGE of purified complexes.  
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Figure 3.4 
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Figure 3.4. Crystal structures of a Get3-Get4/5 intermediate complex.  
(A) The asymmetric unit of the 2.8 Å structure of Get4/5N (Get4, green and Get5N, gray) 
bound to Get3 (wheat and magenta). (B) Left; one subunit from the 6.0 Å structure containing 
two Get4/5N molecules (Get4, green and Get5N, gray) bound to a Get3 dimer (wheat and 
magenta). Top right; the asymmetric unit of the 6.0 Å structure of Get4/5N (Get4, red and 
Get5N, gray) bound to Get3 (wheat and magenta). The black box outlines one Get3 dimer 
(wheat and magenta) bound to two Get4/5N heterodimers (Get4, red and Get5N, gray). The 
rest of the asymmetric unit is colored as follows: Get3, light gray; Get4, dark gray; Get5N, 
black. Bottom right; Additional view of a subunit from the asymmetric unit of the 6Å Get3-
Get4/5N complex. (C) Comparison of the crystal packing between 2.8 Å Get3/4/5N structure 
(left) and the apo Get3 structure (right, PDB ID 3A37). (D) Two views showing the relative 
orientation of Get4 monomers from the 2.8Å (green) and 6.0Å (red) crystal forms. Alignment 
was based on helices α10 and α11 from the contacting Get3 monomer. 
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Figure 3.5 
 
Figure 3.5. Surface properties of Get3 and Get4. (A) Left, orientation of Get3 used in 
subsequent panels to highlight binding interface. For surface representations one monomer is 
outlined in black and the interaction surface of Get4 on Get3 is highlighted by dashed lines for 
intermediate complex (green) and inhibited complex (blue).  Right, accessible surface color 
ramped based on electrostatic potential from -12 kT/e (red) to +12 kT/e (blue). (B) Surface 
properties of Get4 as in (A), except Get4 is color-ramped from N-terminus (blue) to C-
terminus (red), and Get5N is colored gray. (C) View of the interface from the 2.8 Å structure 
showing interactions between Get4 (green) and Get3 (wheat and purple). Residues colored 
D263 (red) and E307 (blue) were tested for interaction and colored based on phenotype. These 
residues are unique to this interface and are not found in the ATP-bound structure 65. Dashed 
lines represent potential interactions and are labeled with their atomic distances. 
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Figure 3.6 
 
Figure 3.6. Structural overlay comparing the intermediate and inhibited interfaces.  
Two views of the overlay of Get4 from the intermediate complex (green) and inhibited 
complex (blue) on the closed Get3 dimer from CC. The Get4 from OC was orientated by 
aligning helices α10 and α11 on one monomer of Get3. 
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Figure 3.7 
 
Figure 3.7. Get3 D263A is defective for complex formation. 
(A) Sequence alignments of regions involved in contacts in the Get3-Get4 interface using 
ClustalW 61. Sequences are: Scer – S. cerevisiae, Dmel – Drosophila melanogaster, Xlae – 
Xenopus laevis, Drer – Danio rerio and Hsap – Homo sapiens. Helices are indicated above the 
sequence and labeled. Residues enclosed in boxes tested are unique to the OC interface and 
tested . (B) Summary of the data obtained by ITC, pulldown assays, and kinetic experiments. 
ITC data was generated from a single experiment; pulldown experiments were performed in 
triplicate. (C) Top, Representative association rate measurements of Get3 at 260 nM (wildtype, 
E307A) and 500 nM (D263A). Each plot represents the average of ten experiments. Bottom, 
Representative dissociation rate measurements of Get3 (wildtype, E307A, and D263A). Each 
plot represents the average of 3 experiments. (D) Model for effects of Get3 D263A mutation on 
Get3-Get4/5 complex formation. 
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Figure 3.8 
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Figure 3.8. Get3 binds to one-half of the Get4/5 heterotetramer. 
(A) SEC-MALS analysis of the Get3/4/5 complex. (B) Model depicting the NEM accessibility 
of a solvent exposed Cys residue (S48C) on Get4/5 alone and in complex with Get3. (C) 
Results of the Alkylation assay shown in A.  (D) ATP-bound structure of Get3/4/5N (PDB ID 
4PWX) demonstrating the location of Q34C on the Get3-Get4/5 structure. (E) Results of a 
PEGylation assay with Get4/5 alone or in presence of Get3. 
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Tables 
Table 3.1. Summary of crystallographic data 
Dataset 
Intermediate Complexes 
2.8Å 6Å  
Wavelength (Å) 1.0000 0.9795  
Resolution range (Å) 29.8–2.8 (2.9–2.8)a 30.0–6.0 (6.6–6.0)  
Space group P 21212 P 21  
Cell parameters:    
      a, b, c (Å)  112.0, 238.0, 52.2 152.4, 127.3, 210.3  
      α, β, γ (°) 90, 90, 90 90, 110.2, 90  
Unique reflections 34114 (4406) 18388 (4452)  
Completeness (%) 97.0 (95.7) 96.3 (98.7)  
Redundancy 3.3 (3.1) 3.2 (3.4)  
Rmergeb 0.06 (0.58) 0.06 (0.78)  
Mean I/σ(I) 8.3 (1.6) 8.9 (1.4)  
Refinement    
Reflections: work/free 32332/1710 17462/917  
Rwork/Rfree 0.224/0.261 0.274/0.303  
No. protein atoms 7750 41984  
No. ligand atoms 1 4  
Protein B-factors (Å2) 111.0 361.8  
Water/ligand B-fact (Å2) 111.1 357.5  
rmsd of bond lengths (Å) 0.0148 0.0031  
rmsd of bond angles (°) 1.70 0.74  
Ramachandran preferred 96.0% 91.0%  
Ramachandran allowed 3.3% 6.7%  
Ramachandran outliers 0.7% 2.3%  
aValues in parentheses are for the highest resolution shell  
bRmerge = Σhkl Σi |Ii(hkl) − 〈I(hkl)〉|/ Σhkl ΣiIi(hkl), where Ii(hkl) is ith observation of reflection  
hkl and〈I(hkl) is the weighted average intensity for all observations i of reflection hkl. 
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C h a p t e r  4  
CONCLUSIONS 
 
  
In this chapter I will begin by describing our attempts at solving the structure of a full-
length Get3-Get4/5 complex. I will then summarize key findings from our research, and 
highlight areas of study that will help advance our understanding of the role of the Get3-Get4/5 
interaction.  
 
Crystallization of the full-length Get3-Get4/5 complex 
Possibly the most surprising result from our studies of the Get3-Get4/5 interaction was 
that only one binding site on the Get4/5 heterotetramer was occupied by Get3. This 
asymmetrical binding was unexpected because a free Get4/5 heterotetramer forms an extended 
particle in solution, with two available Get3 binding sites on opposite ends of the molecule 36. 
This suggests that Get3 binding to one Get4 forces the Get4/5 heterotetramer to adopt a 
conformation incompatible with binding to a second Get3. However, given our current 
understanding of the full-length Get4/5 molecule, and the lack of a full-length Get3/4/5 
structure, it is unknown how this could occur. To answer this question, we attempted to 
determine a high-resolution crystal structure of the full-length Get3/4/5 complex. 
Using a similar protocol as for the Get3-Get4/5N intermediate complex 65, I was able to 
purify the wildtype Get3-Get4/5 complex in the presence of ADP (Figure 4.1). Crystallization 
trials with this complex produced one hit: 0.02 M Magnesium chloride hexahydrate, 0.1 M 
HEPES pH 7.5, and 22% (w/v) Poly (acrylic acid sodium salt) 5100 (Figure 4.2A). These 
crystals fluoresced under UV (Figure 4.2B), and grew larger when the crystallization 
conditions were optimized (Figure 4.2C). These crystals were very reproducible, but on 
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average only diffracted to ~20 Å. However, a single hexagonal crystal formed that diffracted to 
~8.5 Å (Figure 4.2D-E). Using this dataset, and known high-resolution structures of Get3 and 
Get4/5N as search models, I attempted to solve the structure using molecular replacement 
methods 55, but was unsuccessful.  
To limit the flexibility within the crystal lattice, 22-residues were truncated from the C-
terminus of Get4, which was previously used to produce better-diffracting crystals of Get3-
Get4/5N 65. This led to larger, more three-dimensional crystals (Figure 4.1F), but did not 
improve diffraction. To further stabilize the complex during crystallization trials and improve 
the diffraction limit of these crystals, I purified the Get3-Get4/5 complex in the presence of 
ATP using the catalytically inactive ScGet3 D57V (ScGet3D) 65. Although this complex did 
not crystallize in the initial condition, crystals did form in an entirely different condition: 8% 
(v/v) Tacsimate pH 8.0 and 20% (w/v) PEG 3350. These crystals did fluoresce under UV light 
(Figure 4.1G); however they did not diffract x-rays. Due to the large linker regions and 
inherent flexibility between domains on Get5 36,40, obtaining a high-resolution structure of the 
full-length Get3-Get4/5 complex will be difficult using protein crystallography.  
 
Confirming asymmetry of Get3-Get4/5 binding 
Although crystallizing the full-length Get3-Get4/5 complex may prove too difficult, 
more analytical biochemical methods may provide an alternate route to study the asymmetry in 
Get3-Get4/5 binding. It was previously shown that two different constructs of Get4/5 exchange 
their C-domains to form mixed Get4/5 dimers 36. Thus, one can use this method to generate an 
asymmetric Get4/5 molecule, containing one wildtype Get4 and one mutant Get4 defective for 
binding Get3. This chimeric Get4/5 can then be used in the same kinetic experiments as 
wildtype Get4/5. If the same biphasic association and dissociation are observed with the 
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chimeric Get4/5, then the asymmetry in Get3-Get4/5 binding observed in our initial 
experiments is accurate. 
 
Molecular details of Get3 ATPase inhibition 
The 5.4 Å ATP-bound Get3-Get4/5 structure revealed two functionally distinct binding 
interfaces for anchoring and ATPase regulation 65. The anchoring interface was demonstrated 
to mediate the interaction between Get3-Get4, while the regulatory interface is critical for 
inhibition of Get3 ATP activity. The proximity of the interaction between Get3 Lys69 and 
Get4 Asp74 to the catalytic Get3 D57 suggests that allosteric effects lead to inhibition of Get3 
ATPase activity. However, the sub-atomic resolution prevents direct visualization of these 
changes in our electron density reconstruction 65.  
Unfortunately, a careful examination of the available Get3 structures in different 
nucleotide states suggests that crystallography might not provide us with an answer. Get3 has 
been solved in complex with AMP-PNP 25, ADP-AlF4 24, and ADP 23,25. Although obvious 
conformational changes occur when compared to apo Get3 23,27, there is virtually no difference 
in the active sites of the nucleotide bound structures. The problem is further complicated if 
these changes are due to altered side chain conformations, and not changes in the backbone. 
First, this would require high-resolution data to accurately model the side chains within the 
active site. Second, this would require wildtype Get3 to be used for crystallization, as mutants 
would bias the interpretation of the active site sidechains. Both of these requirements suggest 
that an alternate route to crystallography is required to understand the molecular details of 
Get4-mediated Get3 ATPase inhibition. 
 
Alternate pathways for complex formation 
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In addition to the inhibited complex described in chapter 2, we solved crystal structures 
of the Get3-Get4/5 complex in an alternate conformation. These structures represent an initial 
binding interaction mediated by electrostatics that facilitates the rate of subsequent inhibited 
complex formation. This so-called intermediate complex is supported by a thorough kinetic 
analysis of Get3-Get4/5 complex formation confirming the two-step complex formation. 
Similar mechanisms have been seen in other systems such as Barnase-Barstar 67, and the co-
translational targeting machinery 73. In a role analogous to Get4/5, the SRP RNA not only 
prevents the premature dissociation of SRP and FtsY (Get3 and ATP), but also plays an active 
role in ensuring the formation of productive assembly intermediates (intermediate complex), 
thus guiding the SRP and FtsY through the most efficient pathway of assembly (inhibited 
complex and Get3-TA complex). 
While the intermediate complex definitely forms in yeast, it remains to be seen whether 
the same biphasic Get3-Get4/5 association occurs in other organisms. Sequence analysis of 
Get3 and Get4 homologues suggest that the yeast Get3 D263-Get4 H51 interaction is lost in 
flies and frogs, but then acquired again in fish and mammals (Figure 3.7A). This raises 
multiple questions: Is the intermediate complex essential for efficient TA targeting? Do other 
organisms form an initial Get3-Get4/5 complex different from that in yeast? Only a more 
comprehensive kinetic analysis of Get3 homologues from higher eukaryotes can answer these 
questions.  
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Methods 
Protein cloning, expression, and purification 
The sequences of Get4 and Get5 were cloned as previously described 36. In this study, 
Get4/5 was either full-length or modified by truncating the C-terminus of Get4 (residues 291-
312) 65. All Get4/5 proteins were overexpressed in BL21-Gold (DE3) (Novagen) grown in 
2xYT media at 37 °C and induced for 3h by the addition of 0.5 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG). Cells were lysed using a microfluidizer (Microfluidics) and 
purified as a complex by Ni-affinity chromatography (Qiagen). The affinity tag was removed 
by an overnight TEV protease digest at room temperature while dialyzing against 20 mM Tris 
pH 7.5, 30 mM NaCl, and 5 mM β-mercaptoethanol (BME). A second Ni-NTA column was 
used to remove any remaining his-tagged protein, and the sample was then loaded onto a 6 mL 
Resource Q anion exchange column (GE Healthcare). The peak containing the full-length 
Get4/5 complex was collected and concentrated to a final volume of ~5 mL. This sample was 
further purified using a Superdex 200 16/60 column (GE Healthcare) equilibrated with 20 mM 
Tris pH 7.5, 100 mM NaCl, and 5 mM BME. Fractions containing Get4/5 were pooled and 
concentrated to ~5 mg/mL. 
The S. cerevisiae Get3 coding region was cloned as previously described 23. A 6xHis-
tag followed by a tobacco etch virus (TEV) protease site was fused to the N-terminus, and a 
stop codon was placed in front of the C-terminal 6xHis-tag. All S. cerevisiae Get3 mutants 
were generated using the QuikChange method. All Get3 proteins were made in BL21-
Gold(DE3), grown in 2xYT media, and induced with 0.5 mM IPTG for 16h at 22oC. Cells 
were lysed using a microfluidizer (Microfluidics) and purified by Ni-affinity chromatography 
(Qiagen). The affinity tag was removed by an overnight TEV protease digest at room 
temperature while dialyzing against 20 mM Tris pH 7.5, 100 mM NaCl, and 5 mM BME. A 
second Ni-NTA column was used to remove any remaining his-tagged protein, and the sample 
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was run on a Superdex 200 16/60 column (GE Healthcare) equilibrated with the dialysis buffer. 
Fractions corresponding to a dimer of Get3 were pooled and concentrated to 15-20 mg/mL.  
Get3-Get4/5 and Get3-Get4∆C/5 complex was formed by equilibrating 105 µmol 
Get4/5 with 100 µmol Get3 at room temperature in ~5 mL of 20mM Tris pH 7.5, 10mM NaCl, 
5mM BME, 1mM MgCl2, and 1mM ADP. Prior to complex formation, Get3 had been pre-
equilibrated with 1mM MgCl2 and 1mM for 5min at room temperature. Get3-Get4/5 complex 
was further separated from free Get4/5 using a Superdex 200 16/60 (GE Healthcare) 
equilibrated with 20 mM Tris pH 7.5, 10 mM NaCl, and 5 mM BME. Get3D-Get4∆C/5 
complex was formed as above with ATP substituted for ADP. All complexes were 
concentrated to 10-12 mg/mL before use in crystallization experiments. 
 
Crystallization and data collection 
Purified Get3-Get4/5 complex was concentrated to 10-12 mg/ml and crystal trials were 
carried out using the sitting-drop vapor diffusion method at room temperature by equilibrating 
equal volumes of the protein complex solution and reservoir solution using a TTP LabTech 
Mosquito robot and commercially purchased kits (Hampton Research, Qiagen, Molecular 
Dimensions Limited). The Get3-Get4/5 and Get3-Get4∆C/5 crystals grew in the presence of 
0.02 M Magnesium chloride hexahydrate, 0.1 M HEPES pH 7.5, and 22% (w/v) Poly (acrylic 
acid sodium salt) 5100. The Get3D-Get4∆C/5 crystals grew in the presence of 8% (v/v) 
Tacsimate pH 8.0 and 20% (w/v) PEG 3350. All crystals were cryoprotected by transferring 
directly to 10µL of a reservoir solution supplemented with 20% glycerol before being flash 
frozen in liquid nitrogen. 
All diffraction data was collected on Beamline 12-2 at the Stanford Synchrotron 
Radiation Lightsource (SSRL). A single Get3-Get4/5 crystal diffracted to ~8.5 Å, and multiple 
datasets were collected from this crystal. Integration of the data using MOSFLM 50 produced a 
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9 Å dataset in spacegroup C 2221 with the unit cell dimensions: a = 274 Å, b = 390 Å, c = 111 
Å. Using this dataset, a structure of the full-length Get3-Get4/5 complex could not be 
determined by molecular replacement methods 55. However, a protein crystal with ~50% 
solvent content with these unit cell dimensions, would have enough space for ~2.5 full-length 
Get3-Get4/5 complexes in the assymetric unit 52. 
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Figures 
Figure 4.1 
 
Figure 4.1. Purification of full-length Get3-Get4/5 complex. Left; SEC of Get3, Get4/5, 
Get3-Get4/5, or Get3-Get4∆C/5. Right; SDS-PAGE corresponding to purified complexes on 
left. Lane 1 – ScGet3/4/5, Lane 2 – ScGet3/4∆C/5, Lane 3 – ScGet3(D57V)/4∆C/5. 
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Figure 4.2 
 
Figure 4.2. Crystallization of full-length Get3-Get4/5 Complex. (A) Crystals of full-length 
Get3-Get4/5 complex from yeast. (B) UV image of same drop in (A). (C) Optimized crystals 
using similar condition as in C. (D) Hexagonal crystals using Get3-Get4/5. (E) Diffraction 
image of crystal in (D). The shortest dimension of the image is ~8.5 Å. (G) Image of crystals 
using Get3-Get4∆C/5. (G) UV image of crystals using Get3D-Get4∆C/5. 
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A p p e n d i x  A  
TOWARDS PURIFICATION OF THE GET1/GET2 MEMBRANE PROTEIN COMPLEX 
 
 
Introduction 
The targeting of membrane proteins to their correct location in the cell is a highly 
regulated process 44. The majority of membrane proteins are targeted via the signal recognition 
particle (SRP), which typically recognizes the initial hydrophobic transmembrane domain 
(TMD) as it emerges from the ribosome. However, the ubiquitous TA proteins, defined 
topologically by a single TMD near the C-terminus, are unable to access the SRP pathway. 
Their targeting information, contained solely within their TMD, emerges from the ribosome 
only after protein synthesis is complete and must therefore be targeted to the ER post-
translationally 8,9. In eukaryotes, TA proteins account for at least 1% of the proteome, and are 
involved in many essential cellular processes such as apoptosis, vesicle fusion, and protein 
trafficking 8. 
A dedicated TA targeting pathway was first described almost twenty years ago 8. A 
series of genetic and biochemical experiments in eukaryotes identified the components 
involved in this pathway, and is now recognized as the Guided Entry of TA proteins (GET) 
pathway 19,20,22. In yeast, this pathway consists of at least six proteins, Get1-5 and Sgt2, all with 
homologs in higher eukaryotes 47. The first committed step in TA targeting is the formation of 
the Sgt2/TA complex. TA substrate is then transferred to Get3 in a Get4/5-dependent manner 
34. Extensive structural characterization of Get3, the central TA targeting factor, demonstrated 
that it undergoes ATP-dependent conformational changes from an open to closed form 
required for capturing the TA substrate 23-28,47.  
Once formed, this Get3-TA complex is then localized to the ER by the membrane 
proteins Get1/Get2 (Get1/2), which stimulate release of the TA protein and subsequent 
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insertion into the ER membrane 29-32. Recent cross-linking studies have demonstrated a 
physical link between the TMD of a TA protein and Get1/2, suggesting this complex actively 
assists the TA during insertion, and not only in Get3 recruitment 74. However, the exact 
mechanism for Get1/2 function within this pathway is still largely unknown. This section 
describes the expression and purification of Get1 and Get2 using an E.coli expression system 
in an attempt to obtain a high-resolution crystal structure of the Get1/2 complex. 
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Results/Discussion 
Expression and purification of the individual components Get1 and Get2 from 
Saccharomyces cerevisiae 
Multiple reports have demonstrated that Get1 and Get2 from S. cerevisiae can be 
recombinantly expressed and purified from E.coli, and then reconstituted in proteoliposomes to 
form a functional complex 29,31,74. For this reason, we used E.coli as an expression system to 
generate Get1/2 for crystallization trials. For initial experiments, the full-length Get1 or Get2 
was cloned into pET33b containing an N-terminal 6xHis-tag and TEV cleavage site and 
expressed in Rosetta2 pLysS cells using the autoinduction system 75. Although this system had 
been previously used to express Get1 and Get2 to milligram quantities, our constructs did not 
express (Figure A.1A-B). Comparing our constructs to the ones used previously 29 revealed 
that the sequence encoding our 6xHis-tag was poly-CAC, whereas the constructs in previously 
used in pET28 contained a poly-CAT sequence. Mutating our sequence to a poly-CAT lead to 
a drastic increase in expression and yields of 1-2 mg/L of total protein (Figure A.1C). These 
fractions were then combined and run over SEC, with both Get1 and Get2 purifying over 
multiple elution volumes suggesting that these proteins exist as a heterogeneous population 
(Figure A.1D). In addition, greater than 75% of the sample precipitated out of solution during 
concentration prior to loading onto SEC. The apparent instability and presence of multiple 
species for both Get1 and Get2 could be the reasons that SEC with Get1/2 has never been 
reported. To increase both purity and yield, a 10xHis-tag was introduced in place of the 6xHis-
tag (Figure A.2A-B).  
One reason for Get1/2 crashing out of solution during concentration is that they are 
inherently instable on their own, but form a stable complex together. To test this, individually 
purified full-length Get1 and Get2 were incubated together prior to concentration. Once again 
both proteins precipitated during concentration meaning they were unable to form a complex 
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under these conditions or the complex is also unstable. To further stabilize Get2, the initial 150 
residues were truncated from the N-terminus and replaced with either a 10xHis-tag or an MBP-
fusion. These constructs, expressed to similar levels as full-length Get2 (Figure A.2C-D), but 
were still unstable during concentration. Using more tightly controlled conditions I repeated the 
reconstitution experiments with the purified components (Figure A.2) by varying temperature 
and incubation times. However, the samples were unstable and crashed out under all of these 
conditions.  
One disadvantage in starting with purified components is that Get1 or Get2 is in a state 
that is unfavorable for complex formation. To test this, cells expressing 10xHis-Get1 and 
MBP-Get2 were mixed prior to lysis and extracted and purified together. In this assay, the 
majority of MBP-Get2TM did not form complex (Figure A.3A-B). Until this point, all of the 
above purifications were carried in the presence of LDAO. Therefore, a detergent screen was 
performed to find a different detergent that stabilized complex formation. Using the same assay 
described above with 10xHis-Get1 and MBP-Get2TM, the detergents Fos-Choline 12 (FC12) 
and Anzergent 3-12 increased extraction efficiency and final protein yields, however there was 
only a minor increase in complex formation (Figure A.3C-D). This assay was then scaled up 
and repeated at varying temperatures using the detergents FC12, Anzergent 3-12, and LDAO, 
all which produced similar results (Figure A.4). Anzergent 3-12 contains a very charged head 
group making it somewhat unsuitable for protein purification, whereas FC12 has been 
increasing in popularity due to its structural similarity to lipids found in the membrane bilayer 
and increasing success in solving membrane protein crystal structures 76. Based on these 
results, FC12 appeared to be the best detergent for future experiments.  
 
Co-expression and purification of the fungal Get1/2 complex 
Since reconstituting the Get1/2 complex from the individual components was 
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unsuccessful, co-expression trials were carried out. Initially, Get1/2 was expressed on the same 
transcript with 10xHis-Get1 followed by Get2TM under control of one promoter (Figure A.5A-
B), which did not express (Figure A.5C). Interestingly, swapping the orientation of Get1 and 
Get2TM lead to increase in expression (Figure A.5D-E), however the yields were still very low 
(~50 µg/L). To further increase yields, co-expression was carried out using the Duet system 
(Novagen). In this system, 10xHis-Get1 was cloned into pRSF-Duet, while MBP-Get2TM was 
cloned into pET-Duet (Figure A.5F-G). MBP-Get2TM expressed as before, however His-Get1 
did not express at all (Figure A.5H). This is most likely due to the high copy number of pRSF-
Duet, which could be detrimental to membrane protein production as the kinetics of insertion 
are slower than transcription. Based on copy number pACYC-Duet would be a more logical 
choice instead of pRSF-Duet, unfortunately the Rosetta2 pLysS cells contain a 
Chloramphenicol marker ruling out the possibility of using pACYC-Duet. 
Next, co-expression was carried out using the two-promoter system on the same 
plasmid. Here, MBP-Get2TM was inserted into MCS-1 in pET-Duet, while 10xHis-Get1 was 
inserted into MCS-2. In addition to Sc, Get1/2 was cloned from Candida albicans (Ca) and 
Aspergillus fumigatus (Af). Although both 10xHis-Get1 and MBP-Get2TM expressed very well 
for all species, the majority of MBP-Get2TM was present in the Ni-NTA flow through 
suggesting a stable complex could not be purified (Figure A.6). For Sc and Ca, the Ni-NTA 
elutions were concentrated and then purified over amylose resin. However, the majority of 
Get1/2 complex was found in the amylose flow through (Figure A.6C-D) suggesting that 
complex formation was not favored and further validating the results from Figure 6A-B. To 
determine whether the MBP fusion disrupted Get1/2 complex formation, a 10xHis-tag was 
used in place of MBP, while Get1 remained untagged (Figure A.7A-B). This construct gave 
better expression of the 10xHis-Get2TM, but the final yield was not stoichiometric as Get1 was 
present in roughly half the amount compared to Get2TM (Figure A.7C). To determine whether 
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this contained stable Get1/2 complex, the elution fractions were concentrated and loaded onto 
SEC. While the chromatogram contained multiple peaks, the major peak eluted at ~12.8 mL, 
corresponding to a size of ~80 kDa (Figure A.7D). Running the fractions on SDS-PAGE 
revealed that all of the peaks contained Get2TM, but only the major one also contained Get1, 
suggesting that complex formation occurred, although not stoichiometrically (Figure A.7E). 
Strangely, the Af proteins used in the same construct design did not express to a significant 
amount (Figure A.7F). To understand whether the truncated version of Get2 containing only 
the TMDs was enough for complex formation, we performed the same experiment using full-
length Get2. In this assay, Get2 expressed to a lesser amount than Get2TM, but the complex 
appeared to be more stoichiometric (Figure A.7G). However, concentration of this sample 
again lead to precipitation suggesting that complex formation did not occur.  
One reason for the inability to purify a stable Get1/2 complex from E.coli is that an 
additional factor only found in eukaryotes in required for complex formation or stabilization. 
Indeed, this factor may be Get3, whose recruitment to the ER membrane may either stimulate 
complex formation or stabilize an otherwise weak interaction between Get1 and Get2. To test 
this, full-length Get1/2 were expressed as in Figure 7E, and untagged Get3 was expressed on 
pRSF-Duet. This lead to decreased Get1/2 expression (Figure A.8A) when compared to the 
same construct without Get3. In this experiment, both Get1 and Get2 contain Get3-binding 
domains, which might prevent formation of a stable Get1/2/3 trimer complex and instead 
would cause formation of a heterogeneous population. To stabilize the Get1/2/3 complex, 
Get2TM was expressed instead of full-length Get2, but produced similar results as with full-
length Get2 (Figure A.8B). Overall, this strategy leads to decreased Get1/2 expression (Figure 
A.8) when compared to the same construct without Get3 (Figure A.7A,E). 
Based on the results from Figure 8, it is unclear whether Get3 is not expressing or 
simply not forming a stable complex with Get1/2. Although no bands corresponding to Get3 
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were detected in SDS-PAGE, Get3 expression could not be ruled out because the lack of a tag 
prevents detection in a western blot. To test whether Get3 expressed in this system, an MBP-
Get3 fusion was expressed on pRSF-Duet, along with the Get1/2 constructs in Figure 7. In this 
experiment, Get3 expressed very well, but did not form a stable complex with Get1/2 (Figure 
A.9). Surprisingly, a large fraction of Get3 co-purified with the membrane, but did not form a 
stable complex with Get1/2. To test whether Get3 non-specifically interacted with the 
membrane, the MBP-Get3 fusion was expressed on pRSF-Duet by itself and purified under the 
same conditions. In this experiment, Get3 again interacted with the membrane to the same 
extent as with Get1/2, suggesting that this interaction is non-specific (Figure A.10). Overall, 
this strategy leads to a decrease in Get1/2 expression (Figs. A.8-9) when compared to the same 
constructs without Get3 (Figure A.7). When taken together, the expression and purification 
studies described above suggest that Get1/2 expression in E.coli is not advantageous and that a 
eukaryotic expression system should be used. 
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Methods 
Protein cloning, expression, and purification 
The sequences of Get1 (residues 1-235), Get2 (1-285), and Get2TM (151-285) were 
cloned into pET33 or pET28 as previously described 29. These constructs were further modified 
to contain a 10x-His tag using the QuikChange method. In addition to the his-tagged version, 
Get2TM was fused to an N-terminal Maltose Binding Protein (MBP) followed by a tobacco etch 
virus (TEV) protease site in the pMAL vector. Co-expression vectors were generated using the 
Duet system (Novagen). All constructs were verified by DNA sequencing. All Get1 and Get2 
proteins were overexpressed in Rosetta2 pLysS (DE3) (Novagen) using the autoinduction 
system 75. A single colony was used to inoculate 50 mL Terrific Broth (TB), and grown at 37 
°C to an OD600 ~0.4. 10 mL of this starter culture was used to inoculate 1 L autoinduction 
media and grown at 37 °C for ~16 h. Cells were harvested by centrifugation at 5000 rpm for 
20min at 4 °C, resuspended in lysis buffer (50 mM Na-HEPES pH 7.5, 500 mM NaCl, 10 mM 
β-mercaptoethanol (BME), 20 mM imidazole, and 0.1 mM PMSF), and lysed using a 
microfluidizer (Microfluidics). Following an initial centrifugation of 14,000 rpm for 30 min at 
4 °C, the lysate was collected and centrifuged at 45,000 rpm for 60 min at 4 °C. This 
membrane pellet was then resuspended in lysis buffer and the membrane fraction solubilized 
by addition of 1% (w/v) detergent (2% for CHAPS, CHAPSO, and Deoxy-Big CHAPS). 
Room temperature solubilization was performed for 1 hr, while solubilization at 4 °C was 
performed for 1-16 h. These samples were then centrifuged for 30 min at 4 °C to remove any 
precipitate, and the supernatant was incubated with 0.5 mL Ni-NTA resin (Qiagen) for ~2 h at 
4 °C. The Ni-NTA resin was collected using a 15 mL disposable column (Biorad), and washed 
with lysis buffer 0.1% detergent and 30 mM imidazole. The sample was eluted by addition of 5 
column volumesof lysis buffer containing 0.1% detergent and 300 mM imidazole. TEV 
protease treatments were performed overnight at room temperature while dialyzing against 20 
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mM Na-HEPES pH 7.5, 150 mM NaCl, 5 mM BME, and 0.1 % detergent. A second Ni-NTA 
column was used to remove any remaining his-tagged protein. Size exclusion chromatography 
(SEC) analysis of the affinity purified proteins was performed by loading .5 mL sample onto a 
Superdex 200 10/300 column (GE Healthcare) equilibrated with 20 mM Na-HEPES pH 7.5, 
150 mM NaCl, 5 mM BME, and 0.1 % detergent. Protein samples were visualized by 
coomasie staining with SDS-PAGE or by western blot against the His-tag (Qiagen anti-
PentaHis) or MBP-tag (NEB anti-MBP).  
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Figures 
Figure A.1 
 
Figure A.1. Purification of the individual components Get1 and Get2. (A) Get1 and Get2 
expressed from pET33 containing a poly-CAC 6xHis-tag. (B) Cartoon representation of 
proteins and tags used in the experiment. (C) Get1 and Get2 expressed from pET28 containing 
a poly-CAT 6xHis-tag. (D) SEC of the individual proteins from (C). 
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Figure A.2 
 
Figure A.2. Purification of the individual components Get1, Get2, and Get2TM used in 
reconstitution experiments. SDS-PAGE and Western blots (Anti-His and Anti-MBP) of (A) 
10xHis-Get1 (B) 10xHis-Get2 (C) 10xHis-Get2TM (D) MBP-Get2TM. (E) Cartoon 
representation of proteins and tags used in the experiments. 
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Figure A.3 
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Figure A.3. Detergent screen for Get1/2 complex formation. (A) Initial purification of 
10xHis-Get1 and MBP-Get2TM. The proteins were individually expressed and the cell pellets 
were combined prior to lysis and extraction in LDAO. (B) Cartoon representation of proteins 
and tags used in the experiment. (C) Ni-NTA purification from detergent screen of 10xHis-
Get1 and MBP-Get2TM. (D) Amylose purification from detergent screen of 10xHis-Get1 and 
MBP-Get2TM. 
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Figure A.4 
 
Figure A.4. Scaled up detergent screen with LDAO, Fos Choline 12, and Anzergent 3-12 
for Get1/2 complex formation. Ni-NTA and amylose purification from detergent screen of 
10xHis-Get1 and MBP-Get2TM at (A) 4oC and (B) 25oC. (C) Cartoon representation of proteins 
and tags used in the experiment. 
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Figure A.5 
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Figure A.5. Co-expression of Get1/2. (A-B) Cartoon representation of expression  system (A) 
and the proteins and tags (B) used in the experiment in (C). (C) SDS-PAGE and Western blot 
of 10xHis-Get1-Get2TM. (D) Cartoon representation of proteins and tags used in (E). (E) SDS-
PAGE and Western blots of 10xHis-Get2TM-Get1. (F) Cartoon representation of the Duet 
expression system. (G) Cartoon representation of proteins and tags used in (H). (H) SDS-
PAGE and Western blots of 10xHis-Get1 (pRSF) and MBP-Get2TM (pET). 
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Figure A.6 
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Figure A.6. Co-expression of MBP-Get2TM/10xHis-Get1 in pET-DUET from Sc, Ca, and 
Af. (A-B) SDS-PAGE and Western blots of Ni-NTA purifications from (A) Sc and (B) Ca. (C) 
SDS-PAGE and Western blots of concentrated smaples from (A) and (B). (D) SDS-PAGE and 
Western blots of amylose purifications from Sc and Ca. (E) SDS-PAGE and Western blots of 
Ni-NTA and amylose purifications from Af. (F-G) Cartoon representation of expression system 
(F) and the proteins and tags (G) used in the experiments. 
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Figure A.7 
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Figure A.7. Co-expression of 10xHis-Get2/Get1 in pET-DUET from Sc and Af. (A-B) 
Cartoon representation of expression system (A) and the proteins and tags (B) used in (C,E-F). 
(C) SDS-PAGE of 10xHis-Get2TM/Get1 Ni-NTA purification from Sc. (D) SEC of sample 
from (C). (E) SDS-PAGE of fractions from (D). (F) SDS-PAGE and Western blot of 10xHis-
Get2TM/Get1 Ni-NTA purification from Af. (G) SDS-PAGE of 10xHis-Get2/Get1 Ni-NTA 
purification from Sc. 
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Figure A.8 
 
Figure A.8. Co-expression of 10xHis-Get2/Get1 with untagged Get3 from Sc. (A) Left, 
SDS-PAGE and Western blot of 10xHis-Get2/Get1/Get3 Ni-NTA and amylose purification 
from Sc. Right, cartoon representation of proteins and tags used in the experiment. (B) Left, 
SDS-PAGE and Western blot of 10xHis-Get2TM/Get1/Get3 Ni-NTA and amylose purification 
from Sc. Right, cartoon representation of proteins and tags used in the experiment. 
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Figure A.9 
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Figure A.9. Co-expression of 10xHis-Get2/Get1 with MBP-Get3 from Sc and Af. (A) Left, 
SDS-PAGE and Western blot of 10xHis-Get2TM/Get1/MBP-Get3 Ni-NTA and amylose 
purification from Sc. Right, cartoon representation of proteins and tags used in the experiment. 
(B) Left, SDS-PAGE and Western blot of 10xHis-Get2/Get1/MBP-Get3 Ni-NTA and amylose 
purification from Sc. Right, cartoon representation of proteins and tags used in the experiment. 
(C) Left, SDS-PAGE and Western blot of 10xHis-Get2TM/Get1/MBP-Get3 Ni-NTA and 
amylose purification from Af. Right, cartoon representation of proteins and tags used in the 
experiment. 
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Figure A.10 
 
Figure A.10. Purification of MBP-Get3 from Sc. Left, SDS-PAGE and western blot of Ni-
NTA and amylose purification. Right, cartoon representation of proteins and tags used in the 
experiment.
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A p p e n d i x  B  
CHARACTERIZATION OF AN ARCHAEAL GET3 KNOCKOUT 
 
 
Introduction 
In addition to eukaryotes, tail-anchored proteins are found in both bacteria and archaea 
77. However, given the lack of multiple membrane organelles and the spontaneous membrane 
insertion of TA proteins 7, it is unclear whether these organisms would require a dedicated TA 
targeting pathway. Surprisingly, homologues of the central TA targeting factor Get3 have been 
found in numerous archaeal species 77. Recent studies of these proteins demonstrated they are 
structurally identical to the fungal Get3, and are able to rescue Get3 function in vitro 28,78.  
Archaeal species have been used as model systems for over thirty years, and have been 
useful in studying both the protein translocation channel from Methanocaldocaucus jannaschi 
(M. jannaschii) 79 as well as the proton pump bacteriorhodopsin from Halobacterium 
salinarum (H. salinarum) 80. To determine whether Get3 homologues were essential in 
Archaea, we generated knockout strains of Haloferax volcanii, a model halophilic archaea. 
Using these strains, we set out to address whether a conserved Get pathway exists in Archaea. 
H. volcanii contains two apparent Get3 homologs (annotated Hvo_0724 and 
Hvo_2977), with ~30% sequence identity between the two proteins and ~25% sequence 
identity to ScGet3 28. Although they contain much of the same sequence motifs, Hvo_0724 
contains two distinct regions essential for Get3 function that are absent in Hvo_2977. First, 
Hvo_0724 contains the conserved “CxxC motif” 23-25,28, which tetrahedrally coordinates a zinc 
ion forming the “hinge” that stabilizes the dimer interface 23-25,28. Second, Hvo_0724 contains 
the putative “Get3 motif”, a hydrophobic stretch that is required for binding the TM of a TA 
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protein 24. For these reasons, we believe Hvo_0724 is a Get3 homologue that may function as 
a TA targeting factor in an Archaeal TA targeting pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work was performed in collaboration with Manuela Tripepi from the lab of Mechthild 
Pohlschroder at the University of Pennsylvania. 
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Results/Discussion 
Haloferax volcanii Get3 is not essential 
To gain insight into the physiological roles of these proteins, we generated knockout 
strains in H. volcanii, done through collaboration with Mecky Poehlshroeder’s lab at the 
University of Pennsylvania (Figure B.1A) 81. Growing these strains in a variety of conditions 
did not reveal any differences in growth between the wildtype and knockout strains. To test 
whether there was a functional redundancy between the two genes, we then generated a double 
knockout strain in which both Hvo_0724 and Hvo_2977 were deleted. This also proved to be a 
non-lethal knockout, and showed no phenotypic differences in growth when compared to the 
wildtype strain.  One theory for the presence of these genes in Archaea is that they initially 
functioned in arsenite/arsenate transport and evolved TA-binding capabilities as organisms 
evolved multiple membrane-bound organelles.  However, the double knockout was not more 
sensitive than the wildtype when grown in the presence of either arsenate or arsenite.  This 
result suggests an alternate function for these genes in vivo than simply arsenite/arsenate 
transport. 
To test a wider array of growth conditions, the phenotype microarray system (Biolog) 
was used. This assay can test over five hundred conditions in a 96-well high-throughput format 
82.  Preliminary experiments have given rise to conditions that show a difference in growth 
between the wildtype strain and the double knockout strain (Figure B.1B). While none of the 
compounds are directly involved in TA protein targeting, these results imply that the function 
of either Hvo_0724 or Hvo_2977 becomes essential during stress conditions, similar to growth 
assays in S. cerevisiae 19,23,65.   
One hypothesis for the lack of an obvious phenotype in the initial growth assays is that 
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a chaperone becomes upregulated, which replaces the function of Hvo_0724 and Hvo_2977, 
and rescues growth in the knockout strains. A previous study analyzed the entire transcriptome 
from H. volcanii under different growth conditions 83.  Two genes of interest that were up 
regulated during stress conditions were DnaK (Hsp70 homolog), and Prefoldin Beta, two 
Archaeal chaperones 83,84. Although Archaeal Get3 homologues were demonstrated to bind TA 
proteins in vitro 28, and replace Get3 function in an in vitro TA targeting assay 78, it is unknown 
whether Archaeal Get3 homologues function in TA targeting in vivo. The knockouts described 
here can be used to determine whether TA targeting is defective in these cells, and provide 
insight into the function of Get3 homologues in Archaea. 
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Methods 
Generating H. volcanii knockout strains 
H. volcanii strains were grown at 45 °C in complex medium (CX) or defined medium 
(CA) 81. Plasmid constructs for use in knockout experiments were generated as previously 
described 85. In brief, approximately 700 nucleotides upstream and downstream of the genes 
of interest (Hvo_0724 and Hvo_2977) were cloned into the haloarchaeal suicide vector 
pTA131 86 using a modified version of the overlap PCR method 87.  
Knockout strains were generated using the homologous recombination (pop-in/pop-
out) method as previously described 85. The knockout constructs were transformed into E. 
coli DL739 to first obtain non-methylated plasmid DNA. Using the standard polyethylene 
glycol method, the non-methylated plasmid DNA was used to transform H. volcanii H98 
cells 86. A single homologous recombination event between one of the flanking regions 
cloned into the plasmid and the chromosome (pop in) was selected for by growth on CA agar 
lacking uracil. Recombinants were then grown for 48 h in liquid CA medium supplemented 
with thymidine, hypoxanthine, and uracil to allow a second recombination event, which 
results in excision of the plasmid from the chromosome (pop out). After 48 h, liquid cultures 
were transferred to CA agar plates supplemented with thymidine, hypoxanthine, uracil, and 
5-FOA. These conditions only permit the growth of cells in which the plasmid has been 
excised from the chromosome. Finally, colonies were screened by PCR to confirm the 
knockout. 
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Figures 
Figure B.1 
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Figure B.1. Generating knockouts of Get3 homologues in Haloferax volcanii. (A) PCR 
confirmation of knockouts using flanking primers (1) or gene specific primers (2) for 
Hvo_2799 and Hvo_0724. (B) Conditions from BIOLOG experiments that gave rise to 
difference in growth between H. volcanii wildtype (dashed line) and ∆Hvo_2799/∆Hvo_0724 
(solid line) double knockout strains. The concentration of each compound from left to right is: 
Apramycin (70 µM, 209 µM, 627 µM, 1880 µM); D-Serine (3.1 mM, 9.2 mM, 28 mM, 83 
mM); Isoniazid (0.33 mM, 1 mM, 3 mM, 9 mM); Tobramycin (44.3 µM, 133 µM, 400 µM, 
1200 µM); trans-Cinnamic acid (8.13 µM, 24.4 µM, 73.3 µM, 220 µM). 
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